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Abstract 
In recent times there has been significant debate regarding which is the best dosing regimen for 
vancomycin. An increasing prevalence of invasive Methicillin resistant Staphylococcus aureus 
(MRSA) with reduced vancomycin susceptibility has led authors to advocate target serum trough 
concentrations be increased from 5-10 mg/L to 15–20 mg/L in an effort to curb microbial 
resistance. Higher serum concentrations, however, predispose the patient to an increased risk of 
nephrotoxicity placing the patient at risk of cardiovascular failure (secondary to fluid homeostasis 
disruption) and kidney failure. Minimising these risks is especially important in critically ill patients 
in order to reduce morbidity and mortality.  
Although vast literature evaluating vancomycin-induced nephrotoxicity has been published, most 
analyses rely on small datasets with often inconclusive and/or conflicting results. A project with 
greater statistical power is thus necessary to better describe vancomycin and its relationship to 
nephrotoxicity as well as to evaluate whether the theoretical benefits of continuous infusion of 
vancomycin for minimizing nephrotoxicity translate to clinical practice. Not only will this serve to 
guide clinician prescribing practice, but it will also ensure vancomycin is not prematurely 
disregarded as a treatment option.  
The aim of this thesis is to clarify what concentrations and dosing regimens of vancomycin are 
associated with nephrotoxicity. Specifically, the aims of this thesis are to: 
1. Describe pharmacokinetic and clinically measured variables that are associated with 
vancomycin-associated nephrotoxicity  
2. Determine whether intermittent or continuous infusion dosing of vancomycin is 
associated with greater nephrotoxicity. 
We performed a series of retrospective analyses of over 1500 vancomycin recipients from two 
tertiary intensive care units. Furthermore, a meta-analysis comparing continuous infusion and 
intermittent infusion dosing and the respective incidence of vancomycin-associated nephrotoxicity 
was performed.   Increased serum vancomycin concentrations and duration of therapy were 
identified as pharmacokinetic independent predictors of nephrotoxicity. Additionally, concomitant 
vasoactive therapy, increased illness-severity score and concomitant aminoglycoside use were 
identified as independent clinical predictors of nephrotoxicity. Furthermore, our data convincingly 
shows that administration of vancomycin by continuous infusion is associated with significantly 
less nephrotoxicity than intermittent infusion. Despite these hypothesis-generating findings, we 
believe that a large prospective randomised controlled trial is necessary to categorically determine 
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whether a mortality benefit can be achieved with continuous infusion of vancomycin. 
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1 Introduction  
Staphylococcus aureus is a Gram-positive facultative anaerobic bacterium that is considered normal 
skin flora in most parts of the world. It is though, an opportunistic pathogen and risk of sepsis, 
organ dissemination and abscess formation is high. The current treatment of choice for Methicillin 
resistant S. aureus (MRSA) is vancomycin, a glycopeptide antibiotic that inhibits bacterial cell-wall 
synthesis by binding d-alanyl-d-alanine. Although to date vancomycin has been effective, an 
increased prevalence of MRSA with reduced susceptibility to vancomycin has resulted in guidelines 
recommending increased serum concentrations from 5-10 mg/L to 15-20 mg/L to ensure better 
patient outcomes (1). A primary concern of this recommendation though, is that data strongly 
suggests vancomycin has a  dose-dependent nephrotoxic effect (2-4). 
The extent by which vancomycin is an independent nephrotoxic risk factor is currently disputed 
with literature largely forming inconclusive results. Further, definitive data that demonstrates the 
optimum dosing regimens to minimize nephrotoxicity is required. The failure to form definitive 
conclusions regarding dosing regimens and nephrotoxicity is largely related to previous studies 
relying on small samples sizes and a lack of prospective trials examining the controlled titration of 
vancomycin levels. A series of large studies that can categorically define the risk factors for 
nephrotoxicity and optimum dosing regimens are required to ensure vancomycin’s prescribing 
practice is optimised and the clinical usefulness of this antibiotic is prolonged. This thesis will 
address this. 
The following chapters have been provided. Chapter 2 will provide a literature review of the 
research field. It will discuss MRSA infection in the Intensive Care Unit (ICU) and the impact this 
has on mortality. It will provide a history of vancomycin, its use in ICUs and the clinical 
pharmacology. Furthermore, a review of vancomycin-associated nephrotoxicity will be provided. 
Chapter 3 outlines the aims of this thesis. Chapter 4 includes the 3 manuscripts accepted for 
publication during this thesis: 
1. Vancomycin associated nephrotoxicity in the critically ill: A retrospective multivariate 
regression analysis 
2. Factors associated with vancomycin nephrotoxicity in the critically ill 
3. Vancomycin associated nephrotoxicity. Continuous versus intermittent infusion: A meta-
analysis 
Whilst Chapter 5 outlines the findings of the thesis and discusses potential avenues for future 
research. 
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2 Literature Review 
2.1 Infection in Intensive Care Units 
Infection is a common complication within ICU and accounts for a significant proportion of 
morbidity, mortality and economic burden. Progression to sepsis or septic shock is frequent with 
11.8% of patients admitted to an Australian or New Zealand ICU receiving these diagnoses (5,6). 
Of these patients, 37.5% will die in-hospital – a figure at least double that of non-infected patients 
(6-8). Furthermore, the length of ICU stay increases from an average of 4 to 16 days, obviously 
adding significant strain to health systems worldwide. 
2.2 Methicillin Resistant Staphylococcus aureus 
A large number of pathogenic organisms are commonly identified in Australian and New Zealand 
ICUs. Fortunately, most are susceptible to standard antibiotics. It is concerning, however, that 
within this geographic area methicillin-resistant Staphylococcus aureus (MRSA) is responsible for 
12.1% of all sepsis and septic shock, a figure exceeded only by methicillin-susceptible S. aureus 
(MSSA) (16%) (6,9). Data from the United States indicate that 25.8% of bacteraemias are due to 
MRSA (10,11) causing an attributable mortality of 23.4% (12,13). Additionally, mortality rates 
(both 30-day and in-hospital) have proven significantly higher in patients with MRSA bacteraemia 
when compared with MSSA, even when treated with appropriate antibiotics (13-15). 
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2.3 Vancomycin 
2.3.1 History 
Vancomycin is an amphoteric glycopeptide antibiotic that was isolated in 1953 from Amycolatopsis 
orientalis. The substance (“compound 05865”) was found to be active against most gram-positive 
organisms (including penicillin-resistant Staphylococci), some anaerobic organisms and Neisseria 
gonorrhoeae (14,16-19). Serial passages of Staphylococci showed only a 4-8 fold increase in 
resistance to vancomycin with the same strains increasing their resistance 100000-fold to penicillin 
(20-22). Demand for vancomycin quickly increased and in 1958, vancomycin was approved by the 
US Food and Drug Administration for clinical use. This initial increase was short-lived though, as 
use of methicillin (also approved in 1958) and cephalothin shortly thereafter were favored 
secondary to less obtrusive adverse effect profiles. Vancomycin became a last resort treatment. 
Despite this, the emergence of MRSA and pseudomembranous enterocolitis saw a sharp increase in 
vancomycin prescribing during the early 1980’s (23,24) as studies at the time suggested that 
vancomycin was equally effective against MRSA as standard therapy was against MSSA (25). 
Increased clinical use though, led to gradual resistance, with vancomycin-resistant enterococci 
(VRE) being reported in Europe by 1986 and the US by 1987 (26). Furthermore, MRSA has 
developed low-level resistance to vancomycin with Assadullah et al.  (27) finding that 18% of 
strains have a minimum inhibitory concentration (MIC) greater than 4 mg/L. Additionally, a group 
at the Asan Medical Centre, South Korea, found that about half of MRSA isolates had vancomycin 
MICs ≥ 1.5 mg/L (28) a value often quoted as a high MIC when considering MRSA with reduced 
susceptibility to vancomycin. Given that an increased MIC is consistently associated with a higher 
mortality (29,30), curbing resistance and maintaining clinical efficacy is critical to the ongoing 
usefulness of vancomycin. 
2.3.2 Pharmacokinetics of Vancomycin 
Vancomycin is poorly absorbed by the oral route (31) and thus intravenous administration is 
required for systemic infections. Vancomycin has a volume of distribution ranging from 0.4-1.5 
L/kg (32-36) with up to 50% being bound to plasma proteins (37). Although this is only moderate 
binding, in vitro studies have shown a 1 to 8-fold increase in MIC in the presence of albumin(38). 
As such, the MIC is likely increased in vivo where a vancomycin-protein interaction may occur. 
Vancomycin can be isolated from most body spaces although concentrations are variable and 
penetration into solid organs is traditionally considered poor (39). For example after 1g of 
intravenous (IV) vancomycin one study showed lung penetration of only 41% (40) whilst studies 
analysing cerebrospinal fluid (CSF) concentrations showed CSF-to-serum ratios ranging from 0 to 
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48%, the greater values being observed only in the presence of meningeal inflammation (34,41). 
Vancomycin is eliminated primarily via the renal route with 80-90% of that recovered being 
unchanged (34). Approximately 5.0-8.5% of vancomycin clearance is extra-renal (42). 
2.3.3 Pharmacodynamics of Vancomycin 
By binding d-alanyl-d-alanine cell wall precursors, vancomycin inhibits peptidoglycan cross-
linking and thus inhibits bacterial cell-wall synthesis. Vancomycin acts primarily in a time-
dependent manner although some concentration-dependency has been noted in both animal models 
and human data (43,44). 
Vancomycin concentration targets and dosing regimens to ensure optimal effects remain 
controversial. The Australian Therapeutic Guidelines recommend intermittent infusion (II) of 1.5 
grams 12-hourly when patient creatinine clearance is greater than 90 mL/min (target trough 
concentration 15 ± 3 mg/L) or continuous infusion (CI) of 3 g over 24 hours with target 
concentrations of 20 ± 3 mg/L.  A decreased dose is recommended as kidney function declines with 
dosing monitored and adjusted on the basis of trough and peak vancomycin serum concentrations. 
In vitro, animal, and limited human data suggest that an area under the curve (AUC)/MIC value ≥ 
400 is optimal although no studies demonstrate a strong correlation between this and trough 
concentrations ≥ 15 mg/L (45). 
Studies aiming to identify whether II or CI dosing protocols have optimum bactericidal activity and 
which has fewer adverse effects have yielded inconclusive results. As mentioned, the bactericidal 
activity of vancomycin is primarily time-dependent and higher concentrations do not correlate with 
better outcomes (39,46,47). Administration by II results in more variable concentrations than CI 
(48,49). As such, theoretically, CI should have greater clinical efficacy as peaks and troughs are 
minimised and time above MIC is maximised. Despite this, Wysocki et al. (50) were unable to 
demonstrate any significant advantage of CI over II when comparing microbiological outcomes in 
119 critically ill patients. This may be explained by the fact that when compared with beta-lactam 
antibiotics vancomycin may have a longer post-antibiotic effect (bactericidal activity after 
concentrations fall below MIC) thus lessening the importance of maintaining serum concentrations 
above the MIC (51,52). Moreover, confirming these findings, Cataldo et al. (53) were unable to 
demonstrate a significant difference in mortality rates between both CI and II groups in a meta-
analysis of six studies. 
Despite a lack of data showing significance between CI and II patient mortality and clinical 
outcome, CI reaches target concentrations faster with fewer therapeutic drug monitoring (TDM) 
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samples, has less variability in the daily infused dose, and reduces costs (50). A large study of some 
1,737 patients showed that vancomycin serum trough concentrations were higher in the CI group 
even after two to four II doses (54). Furthermore, 70% of patients dosed within the CI group 
achieved target concentrations, whilst only 34% of patients with II dosing achieved target (39,54). 
Given a 20% reduction in bactericidal response is noted when target drug concentrations are not 
met within 72 hours (55) surrogate outcome data suggests that CI should be beneficial.  
Given this finding, Roberts et al. (56) have suggested that when vancomycin is administered by CI, 
the steady state concentrations should be five to six times the MIC of the infecting organism. 
Achieving these target exposures becomes problematic though when the MIC of the infective 
organism is ≥ 2 mg/L as high serum concentrations are necessary. Although CI of vancomycin is 
associated with a significantly lower risk of drug related nephrotoxicity (53) a clear exposure–
toxicity relationship exists with Ingram et al. (2) demonstrating that a serum concentration ≥ 28 
mg/L markedly increases nephrotoxic risk. Furthermore, Lodise et al. (4) found that serum trough 
concentrations > 20 mg/L are associated with an increased risk of nephrotoxicity with the predicted 
probability of nephrotoxicity being >20% amongst non-ICU patients. Panday et al. (57) thus 
suggested that CI should be restricted to S. aureus infections with an MIC < 1 mg/L. Clearly, when 
treating a patient infected with MRSA that has reduced susceptibility to vancomycin, achieving an 
exposure associated with good microbiological outcomes will be difficult without subjecting the 
patient to undue nephrotoxicity (4,57).  
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2.3.4 Nephrotoxicity 
Early vancomycin research showed a significant nephrotoxic effect, although, this was largely 
associated with poor purification technique of the raw material (58,59). By the late 1970s, as 
purification techniques improved, the associated adverse effects were significantly reduced with 
most studies finding an average nephrotoxicity between 5-7% of patients (19,38,53,60-62). The 
reduced susceptibility of MRSA to vancomycin and the subsequent increase in vancomycin dose 
has renewed interest in nephrotoxicity as increased serum trough concentrations, daily doses >4 
g/day and increased duration of treatment are independently associated with increased risk of 
vancomycin toxicity(63,64). Despite Pritchard et al. (63) evaluating 1504 courses of vancomycin to 
identify these factors, phase 2 of their study (which evaluated patient-specific risk factors 
differentiating nephrotoxic and non-nephrotoxic populations) analysed only 129 patients. Similarly, 
although nephrotoxicity rates as high as 43% have been reported, concomitant nephrotoxic agents 
and differences in baseline severity consistently skew the results (3,4,55,60,65,66). For example, 
Jeffres et al. (3) noted that the 43% of patients (40/94) who developed renal toxicity in their study 
had significantly greater baseline Acute Physiology and Chronic Health Evaluation (APACHE) II 
scores than those who did not. Further, a blood urea nitrogen to serum creatinine ratio >20 and 
administration of vasopressors was also significantly greater amongst patients who developed 
nephrotoxicity. Furthermore, in addition to the above mentioned risk factors, total body weight 
≥101.4 kg, estimated creatinine clearance ≤86.6 ml/min and heart failure have all been 
independently associated with an increased risk (2,58,64). Given the heterogenous population of 
critically ill patients and the fact that by definition, they have higher morbidity, these confounders 
are particularly relevant and need to be accounted for in any future studies. 
Critically ill patients themselves have increased vulnerability to nephrotoxic agents and subsequent 
renal failure due to severity of illness (67). Not only is baseline renal dysfunction more prevalent 
(64), but patients are more likely to have sepsis with organ failure, hypotension requiring treatment 
with vasopressors, diabetes mellitus with microalbuminuria and concomitant nephrotoxic treatment 
(67). Lodise et al. (64) have demonstrated that ICU stay at initiation of treatment is associated with 
increased risk of nephrotoxicity. Further, they note a difference between general patients and those 
in ICU receiving ≥ 4g vancomycin per day and < 4g per day of vancomycin with 35% vs. 39% and 
10% vs 16% respectively developing nephrotoxicity. Complicating matters further, patients with 
sepsis (of which a vast majority are in the ICU) have larger vancomycin volumes of distribution (up 
to twice that of normal) and decreased vancomycin renal clearance (68). This has the two-fold 
effect of both increasing daily-dose requirements and increasing the time-of-exposure in patients 
already vulnerable. Huang et al.  (69) confirmed that serum trough concentrations of vancomycin 
      7 
 
can be higher in critically-ill patients, reinforcing the fact that they are at higher risk of 
nephrotoxicity than the general patient. Given vancomycin clearance is primarily renal, vancomycin 
clearance decreases in a linear fashion with reduced creatinine clearance. This results in a 
vancomycin half-life from 4 – 11 hours (in healthy adults) to 10 – 200 hours in patients with renal 
failure (34). Clearly, this increased exposure can be detrimental.  
A number of nephrotoxicity definitions exist but recent studies refer to the RIFLE and Acute 
Kidney Injury Network (AKIN) classifications of acute kidney injury (AKI) (70,71). RIFLE (Risk; 
Injury; Failure; Loss of function; End-stage kidney disease) classifies three levels of severity, and 
two of clinical outcomes (Table 1). The advantage of these criteria is that severity of impairment is 
scaled and classified and has been validated for use in patients with pre-existing renal disease (72).  
Table 1 Rifle Criteria Classification 
 Serum creatinine concentration criteria Urine output criteria 
Risk Serum creatinine increase to 1.5 fold OR GFR decrease >25% from baseline <0.5 ml/kg/h for 6 hours 
Injury Serum creatinine increase to 2.0 fold OR GFR decrease >50% from baseline <0.5 ml/kg/h for 12 hours 
Failure 
Serum creatinine increase to 3.0 fold OR GFR decrease > 75% from baseline OR 
serum creatinine ≥ 354 umol/L (≥ 4mg/dl) with an acute increase of at least 44 
umol/L (0.5 mg/dl) 
Anuria for 12 
hours 
Loss Persistent acute renal failure = complete loss of kidney function > 4 weeks  
ESKD Complete loss of kidney function for  >3 months  
GFR = glomerulus filtration rate, ESKD = End-stage Kidney Disease 
Although vancomycin-induced nephrotoxicity is considered reversible (60), AKI is associated with 
significantly worse clinical outcomes. Palmieri et al. (73) demonstrated that burn patients managed 
in an ICU who had AKI had significantly higher length of ICU stay (P<0.0001) than those without 
(43 vs 26 days, respectively). Further, those with AKI had 34% mortality whilst all patients who did 
not develop AKI during ICU admission survived. Of note, almost 85% of patients who progressed 
to higher RIFLE classes were on nephrotoxic antibiotics (aminoglycosides and vancomycin) - 
almost all having sepsis. This clearly demonstrates the significance of vancomycin in ICUs as a risk 
factor for nephrotoxicity. Furthermore, it demonstrates the need to provide clear evidence on how 
best to avoid the potential nephrotoxic consequences of vancomycin.  
While several authors and guidelines have advocated increasing serum trough concentrations to >15 
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mg/L in efforts to maintain vancomycin efficacy in the face of rising MICs, there are no data to 
support improvements in clinical outcomes. Jeffres et al. (74) retrospectively analysed 102 MRSA 
health-care-associated pneumonia patients of which 31% died during their hospitalisation. 
Vancomycin serum trough concentrations and AUC values showed no correlation with hospital 
mortality. Hermsen et al. (75) similarly demonstrated no difference between hospital length of stay 
or mortality when comparing patients with higher and lower serum trough concentrations of 
vancomycin. However, they did demonstrate that higher serum trough concentrations were 
associated with consistently higher rates of nephrotoxicity. These findings raise questions 
surrounding the recommendation of high-trough concentrations given the potential negative 
sequelae. 
Inconsistency is rife amongst vancomycin studies. To date, no published data have concluded 
categorically whether vancomycin is an independent risk factor for nephrotoxicity in the context of 
co-morbidities and drug co-administration in the ICU. Low sample sizes are a common theme with 
a search of the literature revealing only two large scale studies (n > 1000) (63,76). Pfeiffer et al. 
(76) identified that cancer, hypertension, and diabetes were the most common co-morbidities 
associated with nephrotoxicity but no conclusions regarding vancomycin as an independent risk 
factor for nephrotoxicity were drawn. Furthermore, as mentioned, small sample sizes in phase 2 of 
the analysis by Pritchard et al.(63) casts doubt as to the degree that vancomycin is an independent 
risk factor.  
The safest mechanism of administration is not certain and as discussed, it is debatable if increasing 
serum trough concentrations does in fact improve clinical outcomes.  Furthermore, although 
duration of treatment, elevated serum trough concentrations and total daily dose have been 
identified as risk factors, the extent by which each contributes is unknown. A large-scale study with 
the primarily goal of ascertaining whether vancomycin is an independent risk factor is clearly 
required. 
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3 Aims and Hypotheses 
This thesis aims to define risk factors of vancomycin nephrotoxicity in an ICU population. 
Conclusions surrounding what serum concentrations and dosing regimens are most associated with 
nephrotoxicity will be sought. Specifically, the aims of this thesis were to:  
1. Describe pharmacokinetic and clinically measured variables that are associated with 
vancomycin-associated nephrotoxicity  
2. Determine whether II or CI dosing of vancomycin is associated with greater 
nephrotoxicity. 
It is hypothesised that: 
1. Vancomycin serum concentrations will correlate with incidence of vancomycin 
nephrotoxicity and thus be a factor predictive of nephrotoxicity, and 
2. Given vancomycin, when administered by CI, has significantly less variability in serum 
concentrations, CI will have fewer adverse effects on renal function. 
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4  Vancomycin Associated Nephrotoxicity in the Critically Ill 
4.1 Chapter Synopsis 
The aim of this chapter is to identify variables predictive of nephrotoxicity in a population of 
critically ill patients. Furthermore, this chapter analyses the incidence and predictive power of 
dosing method in the same patient population. 
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4.2 Published manuscript entitled, “Vancomycin associated nephrotoxicity in the 
critically ill: A retrospective multivariate regression analysis" 
The manuscript entitled, “Vancomycin associated nephrotoxicity in the critically ill: A retrospective 
multivariate regression analysis” has been published by Critical Care Medicine (2014; 42(12) 2527-
2536) (77). 
The co-authors contributed to the manuscript as follows:  
1. Timothy Hanrahan: Statistical analysis and manuscript preparation 
2. Georgina Harlow: Data collection 
3. James Hutchinson: Data collection 
4. Joel Dulhunty: Statistical analysis and manuscript review 
5. Jeffrey Lipman: Manuscript review 
6. Tony Whitehouse: Manuscript review 
7. Jason Roberts: Manuscript review 
The manuscript is presented as submitted: except figures and tables have been inserted into the text 
at slightly different positions. Also, the numbering of pages, figures and tables has been adjusted for 
overall Thesis continuity. The references are found alongside the other references of the Thesis, in 
the section ‘References’.
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4.2.1 Abstract 
Objectives: To evaluate the influence vancomycin dose, serum trough concentration and dosing 
strategy have on the evolution of acute kidney injury in critically ill patients. 
Design: Retrospective, single-centre, observational study. 
Setting: University Hospital Intensive Care Unit, Birmingham. 
Patients: All critically ill patients receiving vancomycin from 1 December 2004 to 31 August 2009.  
Intervention: None. 
Measurements and Main results: The prevalence of new onset nephrotoxicity was reported using 
RIFLE criteria and independent factors predictive of nephrotoxicity were identified using logistic 
regression analysis. Complete data were available for 1430 patients. Concomitant vasoactive 
therapy (OR = 1.633; p < 0.001), median serum vancomycin (OR = 1.112; p < 0.001) and duration 
of therapy (OR = 1.041; p = <0.001) were significant positive predictors of nephrotoxicity. II was 
associated with a significantly greater risk of nephrotoxicity than CI (OR = 8.204; p = <0.001). 
Conclusions: In a large dataset, higher serum vancomycin concentrations and greater duration of 
therapy were independently associated with increased odds of nephrotoxicity. Furthermore, CI was 
associated with a decreased likelihood of nephrotoxicity compared with II. This large dataset 
supported the use of CI of vancomycin in critically ill patients. 
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4.2.2 Introduction 
MRSA is associated with significant morbidity and mortality in the ICU. MRSA is responsible for 
10% of all infections (8) and 14% of all instances of sepsis (78). Furthermore, MRSA is associated 
with a 50% greater likelihood of mortality than MSSA (79). Given that between 19-25% of patients 
colonised with MRSA develop infection, with an overall mortality rate as high as 6.3 per 100 000 
infections (80) effective antibiotic treatment is critical to treatment success.  
Vancomycin is the antibiotic most widely used for the treatment of infections mediated by MRSA 
(81). Of concern, MRSA with reduced susceptibility to vancomycin is increasing in prevalence with 
studies suggesting trough serum concentrations <10 mg/L are associated with the emergence of 
vancomycin-resistant S. aureus (82,83). Subsequently, clinical practice guidelines now advocate 
targeting trough serum concentrations of 15-20 mg/L, which is much higher than the previous target 
of 5-10 mg/L (1,84,85). This increase in the target exposure is considered likely to increase the 
likelihood of concentration-related adverse effects, including nephrotoxicity.  
Some authors have proposed that doses >4 g/day, high serum trough concentrations and an 
increased duration of vancomycin therapy are associated with nephrotoxicity (8,63,64). To date 
though, there is a relative paucity of large-scale data able to measure the significance of 
vancomycin exposure as an independent risk factor for nephrotoxicity.  
This study aimed to evaluate the influence vancomycin dose, serum trough concentration and 
dosing strategy have on the evolution of acute kidney injury in critically ill patients. 
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4.2.3 Materials and Methods 
A retrospective cohort study was conducted on data from the University Hospital Birmingham, a 
tertiary referral and university affiliated hospital. This ICU treats up to 80 critically ill patients at 
any one time and manages approximately 4500 patients annually. The ICU provides local and 
tertiary care for all adult specialties including heart, lung, liver, kidney and bone marrow 
transplantation. The data of all patients who received intravenous vancomycin from 1 December 
2004 to 31 August 2009 was extracted from a central database. The data of patients receiving 
vancomycin by non-intravenous routes were not included in the primary database.  
Local protocol dictated that patients with a central venous catheter receive vancomycin by CI. No 
criteria were established as to which patients should receive vancomycin by II, but typically, this 
would occur if 1) the clinician was not compliant with the protocol or 2) no central line was present. 
Data of those patients by which the dosing method was unknown or those patients who received 
vancomycin by both continuous and II were included in interests of maximising available data. If a 
patient was the recipient of an II, serum concentrations were measured within 30-minutes of the 
next dose. If the patient was on CI, the samples were taken randomly, but at least 18 hours after the 
preceding dose change.  
The study was approved by the South Birmingham Research Ethics Committee (09/H1207/140). 
Data extracted from the hospital’s electronic database included sex, weight (where available), date 
of birth, ethnicity, hospital and ICU admission dates, ICU and hospital discharge dates, hospital 
discharge status, time of vancomycin prescription, administration start times, rate of infusion, 
dosage, serum creatinine concentration at admission, serum creatinine concentration during 
vancomycin therapy, trough serum vancomycin concentration and MRSA status. If multiple trough 
serum vancomycin concentrations were available, the median and maximum measured 
concentrations were recorded.  
As rifampicin’s pulmonary penetration is often considered superior to vancomycin (86) any 
concomitant prescription was included in the analysis to measure effects it may have on clinical 
outcome. Furthermore, given reports of rifampicin renal toxicity (87,88), inclusion allowed analysis 
of its influence on renal function when prescribed simultaneously with vancomycin. Given patients 
included in the analysis were admitted to the ICU, inotrope data were collected to account for 
potential confounding effects on renal function. Sequential Organ Failure Assessment (SOFA) 
(79,89) data were also collected at the start of treatment. With the exception of Glasgow Coma 
Scale (GCS) and blood pressure (BP), all components (ventilation status, worst daily PO2/FiO2 
ratio, highest inotrope use, liver function, platelet count and creatinine concentrations) of the SOFA 
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score were calculated using data collected from the same electronic database. 
Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal 
Disease (MDRD) formula (80,90) for all serum creatinine concentrations obtained throughout the 
ICU stay. The primary endpoint, new onset nephrotoxicity, was defined as an increase in serum 
creatinine concentration ≥50%, a decrease in eGFR ≥25% or a serum creatinine concentration 
≥350 µmol/L (in the setting of an acute increase ≥ 44µmol/L) as per the RIFLE acute kidney injury 
classification system (70). Secondary endpoints were death within 72 hours of the last recorded 
vancomycin dose (irrespective of treatment modality), all-cause mortality and a combined endpoint 
of either death within 72 hours of vancomycin administration or nephrotoxicity.  
The prevalence of new onset nephrotoxicity was reported and univariate analysis was performed to 
determine data distribution and the prevalence of missing data. Data for which no serum 
vancomycin concentration, dosing amount or creatinine concentration were available (n = 755) or, 
which had incomplete SOFA score availability (n = 356) were excluded from analysis. 
Furthermore, where unique patients had multiple ICU admissions during the study period (n = 151), 
only data from the first episode were used. Continuous variables with a normal distribution are 
reported as mean ± standard deviation (SD); non-normal variables are reported as median and inter-
quartile range (IQR). The Pearson product-moment correlation coefficient was used to identify 
highly correlated potential predictive variables (r > 0.8) with the variable most predictive of 
nephrotoxicity included in further analysis. Predictive variables associated with the primary and 
secondary endpoints were explored using logistic regression analysis. Manual and backward 
stepwise techniques were used to identify the model with best fit. Interactions between predictive 
variables were included where multivariate and bivariate findings differed and inclusion of the 
interaction improved goodness of fit. Independent predictive variables with a p-value <0.05 were 
considered statistically significant. Goodness of fit was assessed by the Hosmer and Lemeshow (H 
& L) statistic and the Nagelkerke R2 index. Receiver operating characteristic (ROC) curves were 
used to explore thresholds for nephrotoxicity at different highest measured and median serum 
vancomycin concentrations. Youden’s index was used to identify the optimal threshold for 
maximising sensitivity and specificity at specific threshold values. Statistical analysis was 
performed in SPSS (Version 20.0, IBM Corp. Armonk, NY). 
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4.2.4 Results 
During the study period, 2359 patients were prescribed vancomycin therapy in line with the study 
inclusion criteria. Of these, 2208 were primary admissions, of which 1430 had complete datasets 
(65%). Univariate analysis comparing excluded and included patients showed no significant 
differences between age at admission (p = 0.055), Day 1 MDRD (p = 0.319) or weight (p = 0.349) 
(Table 2).  
Table 2 Comparison of baseline characteristics between patients included and excluded from 
final analysis 
 Excluded 
N = 778 (35%) 
Included 
N = 1430 (65%) 
p-value 
Age at admission 57.95 56.48 0.055 
Day 1 MDRD 72.22 71.01 0.319 
Weight 77.46 76.78 0.349 
MDRD = Modified Diet in Renal Disease 
Median age was 60.0 (45-70) years with 65% (935/1430) male. Median weight was 75.0 (67.0-
86.0) kg. Vasoactive therapy was used in 62% (885/1430) of patients, whilst 6% (92/1430) received 
simultaneous rifampicin therapy. Furthermore, 11% (150/1430) were identified as MRSA positive. 
The median trough serum vancomycin concentration was 15.3 (9.6-19.6) mg/L whilst the median 
length of vancomycin therapy was 4.4 (2.3-8.6) days. The median average dose was 1.7 (1.1-2.1) 
grams of vancomycin per day. The predominant method of administration was CI (46% or 
653/1430), followed by II (28% or 390/1430); 16% (221/1430) received vancomycin by both 
continuous and II, whilst the mode of administration was not described in 11% (150/1430) of 
patients. The median SOFA score (not inclusive of GCS) was 6.0 (4.0-8.0). The prevalence of 
nephrotoxicity in the study population during ICU admission was 21% (300/1430); ICU mortality 
for the study population was 20% (288/1430). Patient demographics are summarised in Table 3. 
Table 4 summarises differences in clinical and demographic variables between patients who did and 
did not develop nephrotoxicity during ICU admission. 
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Table 3 Demographic data (n = 1430) 
Factors N (%) 
Sex (Male) 935 (65%) 
Age (median (IQR)) 60.0 (45-70) 
Weight (median (IQR)) 75.0 (67.0-86.0) 
SOFA1 score (median (IQR)) 6.0 (4.0-8.0) 
Median serum vancomycin concentration (mg/L; median (IQR)) 15.3 (9.6-19.6) 
Average vancomycin dose daily (grams; median (IQR)) 1.7 (1.1-2.1) 
Length of vancomycin therapy (days; median (IQR)) 4.4 (2.3-8.6) 
ICU Mortality 288 (20%) 
Nephrotoxicity 300 (21%) 
Death within 72 hours of last vancomycin 224 (16%) 
Nephrotoxicity or died within 72 hours of cessation 469 (32% 
Continuous Infusion 653 (46%) 
Intermittent Dosing 390 (28%) 
Mixed Dosing 221 (16%) 
Infusion Type 
Unknown 166 (12%) 
Simultaneous vasoactive therapy 885 (62%) 
MRSA2 Positive 150 (11%) 
Simultaneous rifampicin therapy 92 (6%) 
1Glasgow coma scale (GCS) values were not available for inclusion thus SOFA total is SOFA minus GCS. 
2Methicillicin resistant Staphylococcus-aureus 
SOFA = Sequential Organ Failure Assessment, MRSA = Methicillin resistant Staphylococcus aureus, IQR = 
Interquartile range 
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Table 4 Summary of nephrotoxic and non-nephrotoxic groups 
 Nephrotoxicity 
(Median (IQR)) 
N = 300 
Non-nephrotoxic 
(Median (IQR)) 
N = 1130 
Significance (p-
value) 
Age (years) 62.0 (51.0-71.0) 59.0 (44.0-70.0) 0.004 
Sex (Male) 191 (63.7%) 744 (65.8%) 0.482 
Weight (kg) 75.0 (66.0-85.0) 75.0 (67.0-85.7) 0.366 
SOFA score 7.0 (5.0-9.0) 6.0 (4.0-8.0) <0.001 
Median vancomycin serum concentration 
(mg/L) 
18.9 (13.8-22.2) 14.2 (9.2-18.4) <0.001 
Duration of treatment (days) 8.0 (4.0-15.8) 4.0 (2.0-6.9) <0.001 
Average vancomycin daily (grams/day) 1.1 (1.6-0.6) 1.8 (1.3-2.3) <0.001 
Total vancomycin exposure (grams) 8.1 (4.8-13.9) 6.8 (4.0-11.0) <0.001 
Continuous 161 (53.7%) 492 (43.5%) 0.001 
Intermittent 77 (25.7%) 313 (27.7%) 0.001 
Mixed 44 (14.7%) 177 (15.7%) 0.001 
Infusion Method 
Unknown 18 (6.0%) 148 (13.1%) 0.001 
Simultaneous rifampicin 23 (7.7%) 69 (6.1%) 0.327 
MRSA 38 (12.7%) 112 (9.9%) 0.166 
Simultaneous vasoactive prescription 234 (78.0%) 651 (57.6%) <0.001 
1 Calculated by Mann-Whitney U statistic as variables fail Kolmogorov-Smirnov normality testing 
2 GCS values were not available for inclusion thus SOFA total is SOFA minus GCS. 
SOFA = Sequential Organ Failure Assessment, MRSA = Methicillin resistant Staphylococcus aureus, IQR = 
Interquartile range 
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Patients who received vancomycin by II received a significantly lower median average daily dose 
(1.5 [0.9-2.2] grams) than those who received vancomycin by CI (1.7 [1.2-2.1] grams; p = 0.003), 
mixed method administration (1.7 [1.2-2.1] grams; p = 0.020) or unknown method of 
administration (2.0  [1.0-2.1] grams; p = 0.005). Furthermore, patients who received vancomycin by 
II (8.8 [6.5-11.2] mg/L) had a significantly lower median serum vancomycin concentration than 
those who received it by CI (18.4 [15.6-21.2] mg/L; p = <0.001). Table 5 summarizes group 
differences by method of vancomycin administration. 
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Table 5 Summary of patients’ data receiving vancomycin categorised by infusion method 
type. 
Variable 
Continuous 
Infusion  
(n = 653) 
Intermittent 
Infusion  
(n = 390) 
Mixed 
(n = 221) 
Unknown 
(n = 166) P
1 
Sex (Male)(%) 417 (63.9%) 260 (66.7%) 145 (65.6%) 113 (68.1%) 0.685 
Age (median (IQR)) 59 (44-69) 61 (47.8-71) 59 (45-70) 63 (46.8-72) 0.060 
Weight (median (IQR)) 75 (66.1-85) 75 (67.8–88) 75 (65-84.5) 75 (65-87.9) 0.331 
SOFA score (median (IQR)) 7.0 (5.0-9.0) 5.0 (3.0-7.0) 6.0 (3.0-8.0) 6.0 (4.0-8.0) <0.001 
Median serum vancomycin concentration (mg/L; 
median (IQR)) 
18.4 (15.6-21.2) 8.8 (6.5-11.2) 
15.5 (12.1-
19.1) 
11.9 (8.2-
17.7) 
<0.001 
Average vancomycin dose daily (grams; median 
(IQR)) 
1.7 (1.2-2.1) 1.5 (0.9-2.2) 1.7 (1.2-2.1) 2.0 (1.0-2.1) 0.003 
Length of vancomycin therapy (days; median 
(IQR)) 
5.3 (3.4-10.3) 4.4 (2.5-7.3) 5.0 (2.9-9.2) 0.8 (0.4-1.2) <0.001 
ICU Mortality (%) 172 (26.3%) 49 (12.6%) 31 (14.0%) 36 (21.7%) <0.001 
Nephrotoxicity (%) 161 (24.7%) 77 (19.7%) 44 (19.9%) 18 (10.8%) 0.001 
Death within 72 hours of last vancomycin (%) 130 (19.9%) 36 (9.2%) 25 (11.3%) 33 (19.9%) <0.001 
Nephrotoxicity or died within 72 hours of 
cessation (%) 
253 (38.7%) 101 (25.9%) 66 (29.9%) 49 (29.5%) <0.001 
Simultaneous vasoactive therapy (%) 469 (71.8%) 177 (45.4%) 151 (68.3%) 88 (53.0%) <0.001 
MRSA Positive (%) 64 (9.8%) 56 (14.4%) 20 (9.0%) 10 (6.0%) 0.014 
Simultaneous rifampicin therapy (%) 35 (5.4%) 38 (9.7%) 14 (6.3%) 5 (3.0%) 0.009 
Highest measured serum vancomycin 
concentration (mg/L; median (IQR)) 
24.7 (18.7-28.5) 11.8 (8.4-17.2) 
19.9 (15.8-
26.0) 
12.7 (9.0-
19.1) 
<0.001 
Cumulative vancomycin dose (grams; median 
(IQR)) 
9.0 (6.0-14.4) 5.8 (4.0-9.0) 
8.0 (4.7-
13.8) 
2.0 (1.5-3.0) <0.001 
1Calculated by Kruskall-Wallis statistic where variable is linear as variables fail Kolmogorov-Smirnov 
normality testing) 
SOFA = Sequential Organ Failure Assessment, MRSA = Methicillin resistant Staphylococcus aureus, IQR = 
Interquartile range, ICU = Intensive Care Unit 
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ROC analysis indicated that the threshold for development of nephrotoxicity for median 
vancomycin concentration was 17.8 mg/L (sensitivity = 0.60, specificity = 0.71, Youden’s Index = 
0.31, AUC = 0.677) whilst the threshold for highest measured serum vancomycin concentration 
during admission was 23.7 mg/L (sensitivity = 0.65, specificity = 0.74, Youden’s Index = 0.39, 
AUC = 0.727). Table 6 summarises the risk of nephrotoxicity, sensitivity and specificity for 
incremental increases in trough serum vancomycin concentration. 
Table 6 Precision of predicting nephrotoxicity and incremental risk increase of different 
threshold values for highest measured vancomycin serum concentrations 
Threshold level 
(mg/L) 
Nephrotoxicity 
(%) 
Relative Risk 
Increase1 Sensitivity Specificity YI
 PPV NPV 
10 21.7% - 1 0.043 0.043 0.217 1 
15 23.2% 1.069 0.936 0.178 0.115 0.232 0.914 
20 26.2% 1.207 0.84 0.372 0.212 0.262 0.898 
25 33.1% 1.525 0.747 0.600 0.346 0.331 0.899 
30 41.5% 1.912 0.603 0.774 0.377 0.415 0.880 
>30 47.9% 2.207 0.303 0.912 0.216 0.478 0.831 
1Relative to first threshold level (10 mg/L) 
YI = Youdens index, PPV = Positive predictive value, NPV = Negative predictive value 
 
4.2.4.1 Predictors of nephrotoxicity 
The most parsimonious logistic regression model identified duration of therapy in days (OR = 
1.041; p < 0.001), simultaneous vasoactive therapy (OR = 1.633; p < 0.001) and median trough 
serum vancomycin concentration (OR = 1.112; p < 0.001) as independent positive predictors of 
nephrotoxicity (Table 7). II was associated with a significantly greater risk of nephrotoxicity than 
CI (OR = 8.204; p < 0.001). There was however a significant interaction between median serum 
vancomycin concentration and infusion method. A 1 mg/L increase in the median serum 
vancomycin concentration had lower odds of nephrotoxicity in the II group compared with the CI 
group (OR = 0.92; p = 0.013). There was adequate goodness of fit (Hosmer and Lemeshow test X2 
= 13.31, df = 8, p = 0.102; Nagelkerke R2 = 0.192).  
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4.2.4.2 Predictors of nephrotoxicity or death within 72 hours (combined endpoint)  
Independent positive predictors of nephrotoxicity or death within 72 hours of vancomycin treatment 
(Table 7) SOFA (OR = 1.128; p < 0.001), positive MRSA status (OR = 1.696; p = 0.008), 
simultaneous vasoactive therapy (OR = 1.501 p = 0.008), median vancomycin serum concentration 
(OR = 1.094; p = <0.001) and duration of therapy (OR = 1.032; p = <0.001). There was a 
significantly greater odds of nephrotoxicity or death within 72 hours of dosing in those who 
received vancomycin by II compared to CI (OR = 1.645; p = 0.007). Goodness of fit was adequate 
(Hosmer and Lemeshow test X2 = 14.553, df = 8, p = 0.068; Nagelkerke R2 = 0. 208).  
4.2.4.3 Predictors of death within 72 hours 
Independent predictors of death within 72 hours of the last vancomycin dose showed SOFA (OR = 
1.190; p < 0.001), simultaneous rifampicin therapy (OR = 2.075; p = 0.010) and median trough 
serum vancomycin (OR = 1.034; p = 0.009) as positive predictors (Table 8). The odds of death from 
mixed method dosing (OR = 0.619; p = 0.047) was less than that for patients receiving CI; II was 
non-significantly different to CI (OR = 0.726; p = 0.167). Goodness of fit was adequate (Hosmer 
and Lemeshow test X2 = 5.469, df = 8, p = 0.706; Nagelkerke R2 = 0.113).
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Table 7 Logistic regression analysis with nephrotoxicity and nephrotoxicity OR death endpoints 
Nephrotoxicity Nephrotoxicity OR Death1
All factors Final Model All factors Final Model Factors 
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
Age2  1.032 (0.957-1.114) 0.413 – – 1.072 (0.996-1.153) 1.031 – – 
Weight 0.998 (0.990-1.007) 0.708 – – 1.000 (0.992-1.008) 0.725 – – 
Sex3  0.900 (0.679-1.193) 0.464 – – 1.148 (0.878-1.502) 0.411 – – 
SOFA score4  1.044 (0.997-1.092) 0.065 – – 1.134 (1.085-1.185) <0.001 1.128 (1.080-1.179) <0.001 
Intermittent 1.022 (0.625-1.671) 0.932 8.204 (2.875-23.411) <0.001 1.525 (1.059-2.195) 0.308 1.645(1.149-2.356) 0.007 
Mixed 2.139 (1.251-3.657) 0.005 2.781 (0.661-11.705) 0.163 0.924 (0.645-1.325) 0.504 0.945 (0.660-1.352) 0.755 Infusion Method5  
Unknown 1.267 (0.732-2.194) 0.398 8.050 (2.403-26.967) 0.001 1.431 (0.935-2.191) 0.356 1.487 (0.973 – 2.274) 0.067 
Simultaneous rifampicin prescription 1.029 (0.602-1.757) 0.918 – – 1.305 (0.788-2.162) 0.604 – – 
MRSA Positive 0.865 (0.564-1.326) 0.505 – – 1.644 (1.096-2.466) 0.066 1.696 (1.145-2.511) 0.008 
Simultaneous vasoactive prescription 0.683 (0.496-0.940) 0.019 1.633 (1.226-2.174) <0.001 1.445 (1.066-1.957) 0.003 1.501 (1.111-2.029) 0.008 
Median serum vancomycin (mg/L) 1.104 (1.077-1.132) <0.001 1.112 (1.085-1.139) <0.001 1.088 (1.063-1.114) <0.001 1.094 (1.069-1.120) <0.001 
Median serum vancomycin*Intermittent – – 0.924 (0.868-0.983) 0.013     
Median serum vancomycin*Mixed – – 0.961 (0.889-1.039) 0.314     
Median serum vancomycin*Unknown – – 0.891 (0.838-0.947) <0.001     
Duration of therapy (days) 1.040 (1.027-1.053) <0.001 1.041 (1.028-1.054) <0.001 1.031 (1.019-1.043) 0.187 1.032 (1.020-1.044) <0.001 
 
Goodness of fit: 
 
Hosmer and Lemeshow test 
 
Nagelkerke R2 
 
 
X2 = 10.666, df = 8 
 
0.184 
 
0.221 
 
X2 = 13.307, df = 8 
 
0.192 
 
0.102 
 
X2 = 21.489, df = 8 
 
0.212 
 
0.006 
 
X2 = 14.553, df = 8 
 
0.208 
 
0.068 
                                                 
1 Death during vancomycin dosing or within 72 hours of cessation 
2 Age was re-categorised as an ordinal scale in 10-year increments: Odds >1 is the increase in odds of the outcome within a 10-year increase in the factor 
3 Odds ratio compares female relative to male 
4 GCS values were not available for inclusion thus SOFA total is SOFA minus GCS 
5 Odds ratio is relative to continuous infusion 
SOFA = Sequential Organ Failure Assessment, MRSA = Methicillin resistant Staphylococcus aureus, GCS = Glasgow coma scale 
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Table 8 Logistic regression analysis with death within 72 hours of vancomycin dosing and all-cause mortality as end-points 
Death within 72 hours of vancomycin dosing All-Cause Mortality1
All factors Final Model All factors Final Model Factors 
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
Age2  1.047 (0.957-1.145) 0.318 – – 1.069 (0.984-1.161) 0.116 – – 
Weight 0.997 (0.987-1.006) 0.495 – – 0.994 (0.985-1.003) 0.186 0.992 (0.984-1.001) 0.081 
Sex3  1.203 (0.867-1.670) 0.269 – – 1.197 (0.884-1.619) 0.245  – 
SOFA score4  1.189 (1.126-1.255) <0.001 1.190 (1.133-1.249) <0.001 1.166 (1.110-1.226) 0.000 1.172 (1.121-1.226) <0.001 
Intermittent 0.699 (0.438-1.116) 0.134 0.726 (0.461-1.143) 0.167 0.682 (0.447-1.040) 0.076 0.735 (0.488-1.107) 0.141 
Mixed 0.620 (0.386-0.997) 0.049 0.619 (0.386-0.994) 0.047 0.545 (0.353-0.884) 0.006 0.554 (0.358-0.855) 0.008 Infusion Method5  
Unknown 1.443 (0.906-2.296) 0.122 1.379 (0.878-2.164) 0.163 1.219 (0.781-1.903) 0.384 1.218 (0.784-1.892) 0.380 
Simultaneous rifampicin 1.816 (1.009-3.266) 0.047 2.075 (1.190-3.619) 0.010 1.650 (0.952-2.859) 0.074 1.793 (1.055-3.046) 0.031 
MRSA Positive 1.370 (0.834-2.251) 0.214 – – 1.373 (0.868-2.171) 0.176 – – 
Simultaneous vasoactive prescription 1.045 (0.707-1.543) 0.826 – – 1.134 (0.795-1.618) 0.488 – – 
Median serum vancomycin (mg/L) 1.030 (1.002-1.058) 0.032 1.034 (1.008-1.060) 0.009 1.030 (1.005-1.056) 0.020 1.038 (1.014-1.063) 0.002 
Duration of vancomycin therapy (days) 1.006 (0.997-1.015) 0.215 – – 1.014 (1.005-1.023) 0.003 1.015 (1.006-1.024) 0.001 
Nephrotoxicity 0.932 (0.644-1.350) 0.709 – – 1.199 (0.863-1.668) 0.279 – – 
 
Goodness of fit: 
 
Hosmer and Lemeshow test 
 
Nagelkerke R2 
 
 
Χ2 = 2.969, df = 8 
 
0.120 
 
0.936 
 
Χ2 = 5.469, df = 8 
 
0.113 
 
0.706 
 
Χ2 = 10.586, df = 8 
 
0.146 
 
0.226 
 
Χ2 = 7.560, df = 8 
 
0.139 
 
0.478 
                                                 
1 Death during ICU admission 
2 Age was re-categorised as an ordinal scale in 10-year increments: Odds >1 is the increase in odds of the outcome within a 10-year increase in the factor 
3 Odds ratio compares female relative to male 
4 GCS values were not available for inclusion thus SOFA total is SOFA minus GCS 
5 Odds ratio is relative to continuous infusion 
 
SOFA = Sequential Organ Failure Assessment, MRSA = Methicillin resistant Staphylococcus aureus, GCS = Glasgow coma scale 
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4.2.4.4 Predictors of all cause mortality 
SOFA (OR = 1.172; p < 0.001), simultaneous rifampicin therapy (OR = 1.793; p = 0.031), median 
trough serum vancomycin (OR = 1.038; p = 0.001) and duration of vancomycin therapy (OR = 
1.015; p = 0.001) were significant positive predictors of all-cause mortality (Table 8). Weight was 
non significantly negatively predictive of mortality (OR = 0.992; p = 0.081). II (OR = 0.735; p-
value = 0.141), and mixed method dosing (OR = 0.554; p = 0.008) had lower odds of death than 
participants receiving vancomycin by CI. There was adequate goodness of fit (Hosmer and 
Lemeshow test X2 = 7.560, df = 8, p = 0.478; Nagelkerke R2 = 0.139). 
4.2.5 Discussion 
There are few large-scale studies examining the influence of vancomycin therapy on nephrotoxicity 
in critically ill patients. The need to better understand the vancomycin exposure-toxicity 
relationship is important given recent guidelines advocating higher serum trough concentrations to 
counter the decreasing susceptibility of MRSA (84,85). In this study of 1430 critically ill patients, 
we found that elevated median trough serum vancomycin concentration is associated with a 
significant increase in risk of nephrotoxicity with each 1 mg/L increase in concentration associated 
with a 11.2% increase in the odds of nephrotoxicity. Duration of therapy was also positively 
predictive of nephrotoxicity with every 1 day increase in the duration of therapy being associated 
with a 4.1% increase in the odds of nephrotoxicity. 
These findings are in concordance with other studies that show duration of vancomycin therapy to 
have a significant positive association with nephrotoxicity (3,55,64). Of interest, Pritchard et al. 
(63) noted a significant rising trend in vancomycin serum concentrations (p < 0.001) without an 
increase in the incidence of nephrotoxicity during the same period. This finding, however, may be 
confounded by the association of increasing serum trough concentrations with a decreasing duration 
of therapy during the same period. We hypothesise that if organisms with reduced susceptibility to 
vancomycin continue to become more prevalent, then the potential combination of increased 
duration of treatment and higher trough serum concentrations may result in a further increased 
incidence of nephrotoxicity. 
We found that CI was significantly less likely to cause nephrotoxicity in multivariate analysis than 
all other infusion types despite patients on CI receiving greater daily doses than those receiving II 
of vancomycin. Patients who received II had an 8.2 times higher odds of nephrotoxicity than those 
who received CI and this effect was independent of baseline renal function and serum vancomycin 
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concentration. This confirms the conclusion reached in a recent meta-analysis that suggested CI is 
associated with a significantly reduced risk of nephrotoxicity compared with II (RR = 0.6, 95% CI 
0.4-0.9; p = 0.02)(53). Moreover, mixed and unknown dosing strategies were associated with lower 
odds of nephrotoxicity than II. This is expected, due to the fact that the latter categories likely 
consist of a large proportion of patients dosed by CI in accordance with unit protocol. Furthermore, 
it has been shown that up to 70% of patients dosed within the CI group achieved target 
concentrations, whilst only 34% of patients with II dosing achieved target (54). Given the rise in 
trough concentration recommendations over the study period (85), the II group may have simply 
been undertreated.  
The higher prevalence of nephrotoxicity in the CI group compared with the II group (24.7% vs. 
19.7%) in bivariate analysis deserves mention as this suggests the possibility of confounding. As 
described above, the median serum vancomycin concentration was significantly higher in patients 
receiving CI and this was identified as the main factor hypothesised to be responsible for this 
confounding effect (Table 5). In addition, there was a significant interaction between median serum 
vancomycin concentration and infusion method in multivariate analysis, such that an increase in 
median serum concentration was associated with a higher odds of nephrotoxicity in those who 
received vancomycin by CI compared with those with II. As discussed previously, 66% of patients 
receiving II do not reach target concentrations. Therefore, it could very well be that an increasing 
serum vancomycin concentrations is associated with increasing nephrotoxicity in the CI group. 
Again, AUC would be ideal to study this relationship. 
To our knowledge this is the first large-scale study that has shown vancomycin administration by CI 
is associated with decreased nephrotoxicity. Unfortunately, the decrease in acute kidney injury 
associated with CI does not translate to improved mortality. II was associated with a non-significant 
lower odds of mortality than CI (p = 0.141).  A greater percentage of the cohort received CI (Table 
3) and the duration of treatment and median SOFA score were both higher in the CI group (Table 
5), alluding to potential non-measured factors confounding the result. Given local protocol dictates 
that prescription of vancomycin by CI can only be administered by central line, and inherently, a 
patient requiring central access is likely to have greater morbidity, CIs being more predictive of 
mortality than II in this cohort is not surprising. A large prospective study is required to 
categorically determine the effect of treatment method on mortality. 
In addition to being associated with nephrotoxicity, duration of vancomycin therapy also appears 
positively predictive of all-cause mortality. We are, however, unable to speculate on why this is the 
     
     
      28 
 
case as information on the indication for vancomycin therapy, infection site and sensitivities of the 
targeted organism are unknown. These factors may all contribute to extended vancomycin regimens 
in the context of greater morbidity. It is interesting to note that although nephrotoxicity was 
positively associated with mortality in the enter model, it was not included in the final logistic 
regression model due to poor significance. We hypothesise that follow up at 28 days, or later, would 
identify this trend as significant. 
The analysis included in this study provided interesting results. In phase 1 of their study, Pritchard 
et al. (63) showed that a median trough vancomycin serum concentration of 14 mg/L was the 
threshold for development of nephrotoxicity. Here we have shown that maximum sensitivity and 
specificity for nephrotoxicity occurred at a median concentration of 17.8 mg/L. Though not a large 
increase in concentration compared with Pritchard et al. (63), our study suggests that the lower 
spectra of recommended serum concentrations are relatively safe. In clinical practice, the median 
concentration is not prospectively useful. We found the threshold for nephrotoxicity is 23.7 mg/L 
when considering the highest measured serum concentration observed for a single patient. A 
prudent clinician, with the aid of therapeutic drug monitoring (TDM), thus has the potential to 
negate significant risk of nephrotoxicity by ensuring measured concentrations do not surpass these 
values. Furthermore, it is clear that greater concentrations do have an association with 
nephrotoxicity (Table 6) and this must be considered when targeting high serum concentrations to 
circumvent the challenge of a high MIC. As MRSA MICs continue to rise it will be necessary to 
look to other agents for therapeutic purposes, particularly if the clinical context deems the risk of 
acute kidney injury not tolerable to the patient.  
It must be recognised that this study is limited by its retrospective nature and as such causality 
cannot be demonstrated. An inherent flaw of retrospective data analysis is the difficulty to account 
for all potential confounding variables and simultaneous treatment agents. A prospective 
randomised controlled trial is necessary to confirm these results. While we are able to explore 
factors associated with nephrotoxicity in patients receiving vancomycin, we are unable to quantify 
the overall risk of nephrotoxicity associated with vancomycin use in a general ICU population. We 
also acknowledge that SOFA has not been validated for tracking the severity of illness in ICU. 
Despite this, inclusion of this SOFA score allowed for the degree of morbidity to be partially 
accounted for in the multivariate analysis. Furthermore, the titration of vancomycin dosing based on 
MDRD determinations of eGFR is not validated and may not be optimal. Finally, generalisability to 
other ICU population groups needs to be ensured by validation with an independent dataset. 
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In summary, we have shown that trough serum vancomycin concentrations and duration of therapy 
are associated with increased risk of nephrotoxicity. Further, baseline organ function (SOFA) and 
simultaneous vasoactive therapy are predictive of nephrotoxicity. Given recommendations to 
increase serum vancomycin concentrations to 15-20 mg/L to combat rising MICs, these data 
reinforce the valuable role that TDM plays in optimising safe vancomycin therapy. We have also 
demonstrated that CI is associated with significantly less nephrotoxicity than dosing by II. Despite 
this, there is still a lack of data showing whether the method of administration impacts on all-cause 
mortality and resolution of infection, despite our results showing a small non-significant trend 
towards survival advantage in the II cohort. Given that CI is associated with decreased 
nephrotoxicity, reaches target concentrations faster with fewer samples (when loading doses are 
used) (32,56), has less variability in the daily infused dose, reduces costs (50) and has less 
variability in serum concentrations (48), this large dataset supports use of CI of vancomycin in 
critically ill patients. 
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4.3 Published manuscript  entitled,  “Factors associated with  vancomycin nephrotoxicity  in  the 
critically ill” 
The manuscript entitled, “Factors associated with vancomycin nephrotoxicity in the critically ill” 
has been accepted by Anaesthesia and Intensive Care for publication. 
The co-authors contributed to the manuscript as follows: 
1. Timothy Hanrahan: Statistical analysis and manuscript preparation 
2. Chaitanya Kotapati: Manuscript preparation and data collection 
3. Matthew J Roberts: Data Collection 
4. James Rowland: Data collection 
5. Jeffrey Lipman: Manuscript review 
6. Jason A Roberts: Manuscript review 
7. Andrew A Udy: Manuscript review 
 
The manuscript is presented as submitted: except figures and tables have been inserted into the text 
at slightly different positions. Also, the numbering of pages, figures and tables has been adjusted for 
overall Thesis continuity. The references are found alongside the other references of the Thesis, in 
the section ‘References’.
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4.3.1 Summary 
Vancomycin is a glycopeptide antibiotic commonly used in the management of MRSA infection. 
The recent increase in prevalence of MRSA with reduced susceptibility to vancomycin has 
prompted experts to advocate for higher target trough serum concentrations. This study aimed to 
evaluate the potential consequences of more aggressive vancomycin therapy, by examining the 
association between higher serum concentrations and AKI in a population of critically ill patients.  
We collected data for all patients who received vancomycin over a 5-year period, and evaluated the 
prevalence of new onset AKI using the RIFLE kidney disease criteria.  One-hundred and fifty-nine 
patients provided complete data, with 8.8% manifesting new onset AKI while receiving 
vancomycin. The median age was 57 (44 - 68) years, whilst the median trough serum concentration 
was 16 (10 – 19) mg/L.  Multivariate logistic regression analysis identified mean trough 
concentration (OR = 1.174; p = 0.024), APACHE II score (OR = 1.141; p = 0.012) and 
simultaneous aminoglycoside prescription (OR = 18.896; p = 0.002) as significant predictors of 
AKI. These data suggest higher trough vancomycin serum concentrations are associated with 
greater odds of AKI in the critically ill. 
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4.3.2 Introduction 
Vancomycin is a glycopeptide antibiotic commonly used to treat MRSA and coagulase negative 
staphylococci infections in the critically ill (91,92). Recently, there has been an increase in the 
prevalence of MRSA with reduced susceptibility to vancomycin, with serum concentrations <10 
mg/L associated with the emergence of vancomycin-resistant Staphylococcus aureus. (85). 
Subsequently, current consensus guidelines now recommend a target serum vancomycin trough 
concentration between 15 and 20 mg/L(84). Given the historical target was 5 to 10 mg/L (1), there 
is a relative paucity of data examining the effect of more aggressive drug exposures on the 
incidence of vancomycin associated adverse effects - especially in the critically ill. 
Vancomycin associated nephrotoxicity has been reported in up to 40% of recipients, although the 
exact factors predictive of AKI in this setting are still debated (91). Current data suggest that higher 
daily doses, higher trough serum concentrations, and increased duration of therapy, are associated 
with nephrotoxicity (63,64). Given the baseline risk of developing nephrotoxicity is between 36 and 
67% in the critically ill (depending on the definition employed) (93), there is an imperative  to more 
specifically identify which factors are linked with vancomycin associated AKI, in order to optimise 
clinical efficacy and safety when prescribing this agent. 
As such, our aim was to examine the incidence over a five year period, of new onset AKI in 
critically ill patients admitted to a tertiary-referral hospital, who were receiving vancomycin. 
Furthermore, we aimed to evaluate independent risk factors predictive of AKI in this cohort, with a 
view to informing future dosing practice. 
4.3.3 Methods 
Data were obtained from the institutional database of a large tertiary referral ICU.  This facility 
admits upwards of 2500 patients annually, providing services to all subspecialties excluding 
cardiothoracic and solid organ transplant surgery. Data concerning all patients who received 
intravenous vancomycin therapy, irrespective of indication, for greater than 96hrs, between 1 
January 2004 and 31 December 2008, were extracted for analysis.  The Institutional Review Board 
for Low and Negligible Risk Research approved this study, without the requirement for individual 
patient consent, as per the National Statement on Ethical Conduct in Human Research (2007). 
Baseline variables included; age, sex, weight, date of admission, admission diagnosis, APACHE II 
score (94), and treatment received whilst in ICU. Information pertaining to patient comorbidities 
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was also collected. Patients were excluded from further analysis if they were less than 18 years of 
age, had a baseline serum creatinine concentration >176.8 µmol/L (2 mg/dl) (4), or were receiving 
renal replacement therapy at the time of commencing vancomycin therapy. Vancomycin doses, 
serum concentrations, and baseline renal function for at least two days prior to commencement of 
therapy, were also required for inclusion in analysis. Local protocol dictates that vancomycin dose 
is determined by actual body weight on admission. Given weight was not recorded for all patients; 
it was assumed in such cases that protocol was followed.  
In those patients receiving vancomycin by II, trough serum concentrations were obtained within 48 
hours of commencing therapy, after a minimum of three doses (85). Thereafter, trough serum 
concentrations were collected 30 minutes prior to the next dose. If a patient received vancomycin 
by CI, concentrations were collected at random intervals, but not before 18 hours had elapsed since 
prior dose alteration. The choice of infusion method was ultimately dictated by individual clinician 
preference, though the standard unit protocol was II during the study period. Dosing was 
subsequently adjusted to achieve a vancomycin concentration in the desired range.  Where multiple 
serum vancomycin concentrations were available, mean trough concentrations were calculated for 
use in subsequent analysis. 
AKI was determined using the RIFLE (70) criteria, such that a patient was deemed to have AKI if 
they showed a sustained increase in serum creatinine (>1.5 times baseline) for greater than 48 hours 
duration. Urine output, eGFR and calculated creatinine clearance were not used as a measure of 
renal function, as changes from baseline creatinine are adequately sensitive in detecting AKI 
(95,96). Creatinine serum concentrations were recorded for the duration of ICU admission, though 
only values obtained during vancomycin administration were included in the assessment of 
vancomycin-associated AKI. Vasopressor data, and simultaneous nephrotoxic agent administration 
(including angiotensin converting enzyme inhibitors, diuretics, aminoglycosides, amphotericin, 
iodinated contrast agents, acyclovir, cyclosporin, and nonsteroidal anti-inflammatory drugs) were 
collected as potential confounding variables. 
Continuous data are reported as mean +/- SD where normally distributed, and median, +/- IQR 
where non-normally distributed.  Categorical data are presented as counts (%).  Univariate 
comparisons were made between those with and without new-onset AKI, utilising parametric and 
non-parametric tests of significance as appropriate.  Backwards, stepwise logistic regression 
analysis was used to ascertain a parsimonious model identifying predictors of AKI. Goodness of fit 
was assessed by the Hosmer and Lemeshow (H & L) statistic and the Nagelkerke R2 index. ROCs 
were used to identify thresholds for AKI. A p < 0.05 was considered as statistical significance.  
Analysis was performed in SPSS (Version 20.0, IBM Corp. Armonk, and NY).  
4.3.4 Results 
During the study period, 303 patients were prescribed vancomycin, of whom 251 received this for 
greater than 96 hours.  A further 93 patients were excluded from data extraction, reasons for which 
are presented in Figure 1. One hundred and fifty-eight patients were included in the final analysis. 
 
 
Figure 1 Consort diagram outlining patients selected and omitted from further analysis 
AKI = acute kidney injury, ICU  = intensive care unit. 
 
The median age was 57 (43.75 – 68.25) years, mean APACHE II score 21.32 ± 7.40, and 65.8% 
(104/158) were male. Median vancomycin treatment time was 158 (120 - 234) hours.  The primary 
method of vancomycin administration was intermittent dosing (145/158; 91.8%), whilst two 
patients (1.3%) received vancomycin by CI. Eleven patients (7%) received vancomycin by both CI 
and II.  8.9% (14/158) developed new onset AKI following vancomycin exposure. Twelve (7.6%) 
patients died in ICU. There was simultaneous use of nephrotoxic agents in 70.9% (112/158).  These 
characteristics are summarised in Table 9. 
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Table 9 Summary of demographic data of those patients included in final analysis 
Factors (n = 158) 
Sex (Male) 104 (65.8%) 
Age (median (IQR)) 57 (43.75 – 68.25) 
APACHE (mean ± SD) 21.32 ± 7.40 
Duration of vancomycin therapy (hours; median (IQR)) 158 (120 - 234) 
ICU Mortality 12 (7.6%) 
AKI 14 (8.9%) 
Continuous Infusion 2 (1.3%) 
Intermittent Dosing 145 (91.8%) Infusion Type 
Mixed Dosing 11 (7.0%) 
Simultaneous nephrotoxic agent 112 (70.9%) 
AKI = acute kidney injury, APACHE = acute physiology and chronic health evaluation, ICU = intensive 
care unit, IQR =  Interquartile range, SD = standard deviation.
 
There was no significant difference in the duration of vancomycin therapy amongst those patients 
who developed AKI (175.5 (127.75 – 374.75)) compared to those with did not (158 (117.75 – 
213.75)).  However, patients with AKI were more likely to have sepsis (64.3% vs 36.1%; p = 
0.047), or ischemic heart disease (35.7% vs. 11.1%; p = 0.023), as their primary admission 
diagnosis. Table 10 summarises the key differences between the AKI and non-AKI groups.  
The serum trough concentration threshold with the greatest sensitivity and specificity for AKI was 
16.5 mg/L by ROC analysis (sensitivity = 0.93, specificity = 0.60, Youden’s index = 0.53, AUC = 
0.815).  Backwards logistic regression analysis identified mean trough serum vancomycin 
concentration (OR = 1.174; p = 0.024) and APACHE II score (OR = 1.141; p = 0.012) as 
significant independent positive predictors of AKI. In addition, simultaneous administration of an 
aminoglycoside was the only nephrotoxin identified as being predictive of new onset AKI (OR = 
18.896; p = 0.002). Goodness of fit was adequate (Hosmer & Lemeshow X2 =  1.583, df = 8, p = 
0.991; Nagelkerke R2 = 0.492 summarises the regression analysis (Table 11). 
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4.3.5 Discussion 
In this cohort of critically ill patients treated with vancomycin for greater than 96 hours, new-onset 
AKI was noted in approximately one out of every ten patients.  Higher peak, mean, and initial 
trough vancomycin concentrations were associated with AKI in univariate analysis, although only 
the mean concentration was an independent predictor in regression modelling (OR = 1.174; p = 
0.024).  This means that for every 1 mg/L increase in mean trough serum vancomycin 
concentration, there is a 17.4% increase in the odds of new-onset AKI (Table 11).  
These findings are consistent with Lodise et al. (4) who noted that the mean initial vancomycin 
trough value was significantly higher amongst patients who had nephrotoxicity. Similarly, Pritchard 
et al. (63) identified an increased prevalence of vancomycin toxicity in patients with higher serum 
vancomycin trough values. Interestingly, Pritchard et al. (63) also identified duration of therapy > 7 
days as an independent risk factor for nephrotoxicity. In our study, duration of therapy was non-
significantly greater in the new-onset AKI group, although the sample-size is not sufficient to 
further explore this observation.  
Interestingly, all 14 patients who had new-onset AKI in this cohort had mean trough serum 
vancomycin concentrations > 15 mg/L. Furthermore, ROC analysis identified 16.5 mg/L as the 
concentration with the greatest sensitivity and specificity for new onset AKI. This suggests that 
although greater trough serum vancomycin concentrations may be more efficacious (55,85), this 
may be at the expense of more AKI in a small number of patients.  Prospective studies evaluating 
patients with serum vancomycin concentrations above 15mg/L, compared with those below 15 
mg/L would further elucidate this finding.  
Our study also suggests that concurrent use of aminoglycosides and vancomycin increases the risk 
of new-onset AKI (55,60,85,97).  Specifically, there was an 18.89 (p = 0.002) times greater odds of 
developing AKI in those patients who received aminoglycosides and vancomycin simultaneously. 
Although it is standard practice to use single daily doses at our institution, we did not collect data 
on the type or duration of aminoglycoside therapy in this cohort.  Rather, we only determined if the 
patient had received aminoglycosides of any type, at any time, during their admission. As such, the 
precise impact of aminoglycosides cannot be determined accurately, although a relationship appears 
to exist, mandating further research. 
We included APACHE II in the multivariate model to account for illness severity (94). The mean 
APACHE II score in patients who developed AKI was non-significantly higher in univariate 
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analysis (25.86 vs 20.88; p = 0.107). Nevertheless, APACHE II was identified as a significant 
independent risk factor in regression modeling.  In this case, every one-figure increase in APACHE 
II score is associated with a 14.1% increase in the odds of AKI. This is perhaps not that surprising, 
although it does suggest that those patients with greater illness severity are at higher risk of AKI in 
the setting of vancomycin therapy. Moreover it highlights the value of careful TDM and tracking of 
renal function in such patients. 
Similarly, there was a significantly higher rate of AKI in patients that were diagnosed with sepsis at 
the time of admission. However, this was not an independent predictor of AKI in our multivariate 
model, a finding contrary to other studies (98).  Patients with sepsis have a larger vancomycin 
volume of distribution (up to twice that of normal) and decreased vancomycin renal clearance, as 
compared with the general population (68). This has the two-fold effect of both increasing daily-
dose requirements, and increasing the duration-of-exposure in patients already vulnerable to AKI. 
Given vancomycin clearance is primarily renal (34), vancomycin clearance decreases in a linear 
fashion with reduced creatinine clearance. This serves to increase the half-life from 3-9 hours (in 
healthy adults) (34) to up to 180 hours in those with severe renal failure (99).  As such, we postulate 
that having a diagnosis of sepsis would likely contribute to new-onset AKI with vancomycin 
therapy, notwithstanding the results of our multivariate analysis.  
No significant increase in AKI was seen amongst patients receiving vancomycin and inotropes, a 
finding disparate with previous reports (3,100). Furthermore, despite AKI being an established 
independent risk factor for increased mortality (73,101), we were not able to demonstrate this. 
There was however a non-significant trend towards increased mortality in those with new-onset 
AKI in univariate analysis.  These observations, seemingly at odds with current literature, are likely 
attributable to the low incidence of AKI in our study cohort. 
This study is limited by its retrospective design, in that causality cannot be determined. 
Additionally, we cannot account for all potential confounders, only those that were collected and 
included in multivariate analysis. Ideally, a prospective trial would confirm these results. We also 
acknowledge that the sample size may not be sufficient to identify all predictive factors with 
absolute certainty, especially as we have reported a lower rate of AKI compared with previous 
literature (91). It should be noted that we have also excluded patients with a baseline creatinine 
greater than 176.8 µmol/L (4); a group at high risk of developing AKI.  As such, these data cannot 
be generalised to all patients in the ICU. Furthermore, we did not include any long-term morbidity 
and mortality data in the study, so we are unable to determine the lasting significance of these 
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findings. 
In conclusion, these data confirm higher trough serum vancomycin concentrations are associated 
with greater odds of new-onset AKI in the critically ill, although absolute cause and effect remains 
uncertain.  Our findings also underscore the importance of strict TDM and dose adjustment of 
vancomycin (102-104), particularly with the significant alterations in pharmacokinetics commonly 
encountered in these patients.  This is especially important in those with higher baseline illness 
severity, as this appears to be an important risk factor for new onset AKI in this setting.  As this 
sub-group often require empirical antibacterial therapy, use of vancomycin TDM should be 
considered mandatory, with the avoidance of supra-therapeutic concentrations.  Future prospective 
research should now systematically evaluate the impact of aggressive vancomycin exposure on both 
clinical efficacy, and toxicity. 
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Table 10 Comparison of patients who developed AKI versus those who did not whilst 
receiving vancomycin in the ICU 
 AKI (median (IQR)) 
n = 141 
Non AKI (Median (IQR)) 
n = 144 
p-value 
Age (years) 63 (54.25 – 72.50) 55.5 (43.00 – 68.00) 0.083 
APACHE (mean ± SD)2 25.86 ± 10.58 20.88 ± 6.91 0.107 
Length of ICU stay (days) 11 (4.75 – 27.25) 16 (9 – 22) 0.317 
Trauma 0 (0%) 24 (16.7%) 0.130 
Sepsis 9 (64.3%) 52 (36.1%) 0.047 
Postop 6 (42.9%) 44 (30.6%) 0.374 
Diagnoses 
Respiratory Failure 10 (71.4%) 66 (45.8%) 0.093 
Highest trough concentration 
(mg/L) 
28.00 (25.00 – 37.25) 22.00 (13.00 – 27.00) <0.001 
First trough concentration (mg/L) 21.00 (14.00 – 27.50) 10.00 (6.00 – 17.00) <0.001 
Mean trough concentration (mg/L) 20.00 (17.00 – 29.00) 15.00 (10.00 – 19.00) <0.001 
Duration of vancomycin therapy 
(hours) 
175.50 (127.75 – 374.75) 157.50 (117.75 – 213.75) 0.268 
Sex (Male) 10 (71.4%) 94 (65.3%) 0.773 
Continuous Infusion 0 (0%) 2 (1.4%) 
Intermittent Dosing 14 (100%) 131 (91%) 
Infusion 
Method 
Mixed 0 (0%) 11 (7.6%) 
0.502 
ICU Mortality 2 (14.3%) 10 (6.9%) 0.280 
Diabetes Mellitus 2 (14.3%) 19 (13.2%) 1.000 
Hypertension 5 (35.7%) 47 (32.6%) 0.775 
IHD/CAD 5 (35.7%) 16 (11.1%) 0.023 
Aminoglycosides 10 (71.4%) 52 (36.1%) 0.019 
Aciclovir 2 (14.3%) 12 (8.3%) 0.358 
Cyclosporin 0 (0%) 3 (2.1%) 1.000 
Steroids 3 (21.4%) 36 (25%) 1.000 
IV Contrast 1 (7.1%) 35 (24.3%) 0.193 
NSAIDS 0 (0.0%) 5 (3.5%) 1.000 
Amphotericin 2 (14.3%) 6 (4.2%) 0.150 
ACEi or ARB 2 (14.3%) 19 (13.2%) 1.000 
Vasopressors 12 (85.7%) 96 (66.7%) 0.228 
1 Reported as median (IQR) as data was non-normally distributed as per significant Shapiro-
Wilk normality 
2 Reported as mean ± SD as data was normally distributed as per non-significant Shapiro-Wilk 
normality test 
ACEi = angiotensin-2 converting enzyme inhibitor, APACHE = acute physiology and chronic 
health evaluation, ARB = angiotensin-2 receptor blocker, CAD = coronary artery disease, 
ICU = Intensive care unit, IHD = ischaemic heart disease, IQR = Interquartile range, IV = 
intravenous, NSAID = non-steroidal anti-inflammatory drug, SD = standard deviation. 
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Table 11 Multivariate analysis identifying risk-factors associated with vancomycin associated 
AKI. 
AKI 
All factors Backwards LR1 Variables 
OR (95% CI) P-value OR (95% CI) P-value 
Age2 1.368 (0.720 - 2.599) 0.338 – – 
Sex3 1.198 (0.222 – 6.476) 0.834  –– 
APACHE II 1.146 (0.999 – 1.314) 0.052 1.141 (1.029-1.265) 0.012 
Highest Trough Concentration 1.035 (0.928 - 1.154) 0.540 – – 
First Trough Concentration 1.100 (0.973 - 1.245) 0.129 1.103 (0.979-1.243) 0.106 
Mean Trough Concentration 1.127 (0.916 - 1.387) 0.257 1.174 (1.021-1.349) 0.024 
Duration of therapy 0.999 (0.993 - 1.005) 0.774 – – 
Vasoactives4 1.265 (0.179 - 8.913) 0.814 – – 
Sepsis4 1.495 (0.272 - 8.230) 0.644 – – 
Aminoglycosides 21.312 (2.082 – 218.133) 0.010 18.896 (2.980-119.809) 0.002 
Aciclovir 1.119 (0.072-17.447) 0.936 – – 
Steroids 1.421 (0.168-12.058) 0.747 – – 
IV Contrast 0.563 (0.040 – 7.871) 0.670 – – 
Amphotericin 2.755 (0.079 - 95.812) 0.576 – – 
Concomitant 
nephrotoxic 
agents4 
ACEi or ARB 2.152 (0.209 - 22.138) 0.519 – – 
Goodness of Fit: 
Hosmer & Lemeshow test 
Nagelkerke R2 
 
X2 = 0.739, df = 8 
0.522 
0.999 
 
X2 = 1.583, df = 8 
0.492 
0.991 
1Logistic Regression 
2Age was re-categorised as an ordinal scale in 10-year increments: Odds >1 is the increase in odds of the 
outcome within a 10-year increase in the factor. 
3 The OR is the odds of AKI in a female versus that of a male i.e. Females have a 0.165 lower odds of AKI 
than that of males 
4 Dichotomous variables are expressed as the OR of having or receiving the nominated variable versus not 
ACEi = angiotensin-2 converting enzyme inhibitor, APACHE = acute physiology and chronic health 
evaluation, ARB = angiotensin-2 receptor blocker, CAD = coronary artery disease, ICU = Intensive care 
unit, IHD = ischaemic heart disease, IQR = Interquartile range, IV = intravenous, NSAID = non-steroidal 
anti-inflammatory drug, SD = standard deviation. 
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4.4 Published manuscript entitled “Vancomycin associated nephrotoxicity. Continuous versus 
intermittent infusion: a meta­analysis” 
The manuscript entitled, “Vancomycin associated nephrotoxicity. Continuous versus intermittent 
infusion: a meta-analysis” has been accepted by the International Journal of Antimicrobial Agents 
for publication. 
The co-authors contributed to the manuscript as follows:  
1. Timothy Hanrahan: Data collection, statistical analysis and manuscript preparation 
2. Tony Whitehouse: Manuscript review 
3. Jeffrey Lipman: Manuscript review 
4. Jason Roberts: Manuscript preparation and review 
 
The manuscript is presented as submitted: except figures and tables have been inserted into the text 
at slightly different positions. Also, the numbering of pages, figures and tables has been adjusted for 
overall Thesis continuity. The references are found alongside the other references of the Thesis, in 
the section ‘References’. 
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4.4.1 Abstract 
Vancomycin is a glycopeptide antibiotic widely used in the management of methicillin-resistant 
Staphylococcus aureus. Guidelines currently recommend vancomycin be administered by II, despite 
recent research suggesting CI may be associated with fewer rates of vancomycin-associated 
nephrotoxicity. In 2012, Cataldo et al presented a meta-analysis supporting the use of CI. Here, we 
present an updated meta-analysis, inclusive of a recently published large-scale retrospective study. 
Pubmed, EMBASE and Cochrane review databases were searched using keywords ‘vancomycin’ 
and ‘continuous’ or ‘intermittent’ or ‘infusion’ or ‘discontinuous’ or ‘administration. Seven studies 
were included in final analysis. Using a random effects model, a non-significant trend of reduced 
nephrotoxicity in those who received vancomycin by CI (RR = 0.799, 95% CI 0.523 – 1.220, p = 
0.299) was identified. A large randomised controlled trial is necessary to confirm these results. 
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4.4.2  Introduction 
Vancomycin is an antibiotic widely used in the treatment of MRSA infections. In 2009, the 
Infectious Diseases Society of America (ISDA) advocated vancomycin serum trough concentration 
targets be increased from 5 to 10 mg/L to a now accepted norm of 15 to 20 mg/L to ensure that 
sufficient drug exposures are achieved for less susceptible strains (85). The recommendation for 
higher troughs is potentially problematic with reports of increased nephrotoxicity with increased 
serum trough concentrations >15 mg/L (91).  Consequently, the focus has shifted to identifying 
modifiable risk factors associated with nephrotoxicity and subsequently optimising vancomycin 
therapy to reduce the incidence of nephrotoxicity. 
Recent literature has suggested that vancomycin administered by CI is associated with reduced rates 
(48,77,105) and slower onset (106) of nephrotoxicity when compared with that of II. Furthermore, 
in 2012, a systemic review by Cataldo et al (53) meta-analysed the available published data and 
showed a clear trend towards reduced nephrotoxicity when vancomycin was administered by CI. 
Despite this, guidelines continue to recommend II of vancomycin. Recently, we performed a large 
retrospective multivariate analysis of 1430 patients who received vancomycin in a tertiary hospital 
wherein II was associated with a significantly greater risk of nephrotoxicity than CI (OR = 8.204; p 
≤ 0.001) in multivariate analysis. Here we present an updated meta-analysis, inclusive of all papers 
included in Cataldo et al’s review of nephrotoxicity in CI versus II and, an additional two papers.  
4.4.3 Materials and Methods 
4.4.3.1 Search Strategy, selection criteria and study Selection 
The meta-analysis by Cataldo et al (53) was used as a baseline, with all papers assessable for 
nephrotoxicity included in this study being selected. Furthermore, a search using Pubmed, 
EMBASE and Cochrane review that studied vancomycin and administration method from January 
2012 was also performed. Keyword searches included ‘vancomycin’ and ‘continuous’ or 
‘intermittent’ or ‘infusion’ or ‘discontinuous’ or ‘administration. In view of being consistent, these 
were the same keywords utilised by Cataldo et al (53). Observational studies or RCTs were the only 
publication type included in analysis. Studies were excluded if they were conducted on a paediatric 
population. Abstracts were reviewed and papers assessed for consideration of eligibility. 
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4.4.3.2 Analysed outcomes 
The primary outcome measure was incidence of nephrotoxicity (Table 13). Incidence was compared 
between those who received vancomycin by II and those who received vancomycin by CI method.  
4.4.3.3 Analysis 
To compare results, dichotomous variables were expressed as risk ratios with 95% confidence 
intervals using comprehensive meta-analysis (107). Data was pooled using the random-effects 
model and a summary of the risk ratios of the effects with 95% confidence intervals were 
calculated. The chi-square test was performed to assess heterogeneity with I2 statistic assessing the 
extent. A p-value <0.05 was considered significant.  
4.4.4 Results 
In addition to our recently published study (77), our literature search identified only one additional 
study comparing CI and II to those identified by Cataldo. In total, seven studies were included in 
meta-analysis (48,50,77,105,106,108,109).  
4.4.4.1 Demographics and setting 
All studies were performed in adult tertiary centres with the target pathogen being MRSA and/or 
other gram-positive infections. One study (48) was performed in patients with osteomyelitis and 
thus received vancomycin for extended periods (up to 6 weeks). A proportion of treatment was on 
an outpatient basis (once pharmacokinetic steady-state had been reached). One study (106) analysed 
all patients receiving vancomycin as outpatients,  whilst the remainder (50,77,105,108,109) were 
performed in patients admitted to tertiary intensive-care units (ICU). Overall the mean age was 
56.58 years and the mean duration of treatment was 24.6 days. 70% of patients were male. Of 1534 
vancomycin courses across all contributing studies, 946 (62%) were delivered by CI, whilst 588 
(38%) were delivered by intermittent dosing. 330 (22%) patients developed nephrotoxicity after 
vancomycin administration. A summary of data is included in Table 12. 
4.4.4.2 Methodology used in included studies 
Two studies were RCTs (50,109), two were prospective cohort (48,108) and the remainder were 
retrospective cohort studies (77,105,106)(Table 13). Three studies (48,50,105) targeted serum 
trough concentration of 20-25 mg/L, one targeted 20-30 mg/L (108), one targeted 15-20 mg/L 
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(109),  and the remainder did not specify. Vancomycin administration regimens and AKI definitions 
are outlined in Table 13. 
4.4.4.3 Study Quality and Design 
The quality of the cohort studies included in the analysis were quantified using the Newcastle-
Ottawa scale as developed by Wells et al (110)(Table 14). Three studies were multi-centre 
(48,50,106) whilst the remainder were single-centre, thus there is reasonable external 
generalizability. The RCT performed by Wysocki et al. (50) was well designed with effort to avoid 
bias. As blinding was not possible at the time of administration, a committee, blinded to the 
infusion method, extracted data from charts for analysis. Furthermore, demographic characteristics, 
severity of underlying disease, site of infection, and pathogens were similar in the CI and II groups. 
Similarly, the RCT by Schmelzer et al (109) was well designed with computer-generated 
randomisation however; there is no indication as to whether data extraction and analysis was 
blinded. 
4.4.4.4 Summary of Findings 
Effect sizes of the seven studies are summarised in Table 15 with Figure 2 showing the Forest plot 
for nephrotoxicity. A fixed effects model found a moderate degree of heterogeneity (I2 = 43.67) 
confirming the correct use of random effect model for final analysis. Random effects modelling 
found a non-significant trend of reduced nephrotoxicity in those who received vancomycin by CI 
(RR = 0.799, 95% CI 0.523 – 1.220, p = 0.299).  
Including only the studies that were performed in ICUs, a fixed effects model found an I2 of only 
15.62. For consistency however a random effect model is reported.  Random effects modelling 
found a non-significant higher risk of nephrotoxicity in patients receiving vancomycin by CI (RR = 
1.024, 95% CI 0.765-1.371, p = 0.872). Effect sizes are summarised in Table 16 with Figure 3 
showing the Forest plot for nephrotoxicity in ICU patients.  
4.4.4.5 Discussion 
This meta-analysis has shown that when using a random effects model, CI of vancomycin is 
associated with a non-significant reduced risk of nephrotoxicity when compared to that of II. This is 
despite the largest included study (77) showing a greater percentage of nephrotoxicity in the CI 
group during the univariate analysis. Interestingly, Hanrahan et al (77) showed that II was 
associated with greater odds of nephrotoxicity in the multivariate analysis. This suggests that the 
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univariate analysis of this study was likely influenced by confounders. Of note, SOFA was 
significantly higher in the CI group suggesting pre-existing organ dysfunction was contributing to 
the nephrotoxicity. Given multivariate analysis partially corrects for confounding; it is likely that 
the multivariate analysis from our recent study (77) is a truer representation of effect. Despite this, 
we included the univariate analysis result in meta-analysis for consistency and highlight this as a 
potential limitation of this meta-analysis. 
All 3 studies that reported daily dose noted greater total daily doses in the CI group, yet those who 
report AUC had greater exposure in the II. This is likely due to II having greater maximum serum 
concentrations than CI, perhaps an underlying variable contributing to CIs overall reduced risk of 
nephrotoxicity. In only ICU patients, there was a non-significant trend towards increased risk of 
nephrotoxicity in II. Of note however, given the much larger sample size, our recent study (77) had 
a significantly greater weighting (64.12%) than the other included studies (Table 16). As such the 
abovementioned confounders are likely influencing this result and we acknowledge this to be a 
significant limitation. Furthermore we acknowledge that three of the seven included studies are 
retrospective in nature, which may expose the analysis to confounders. 
4.4.4.6 Conclusion 
There are few large-scale studies that compare the incidence of nephrotoxicity after CI and II. This 
meta-analysis, in addition to recent papers supporting CI, have shown CI should be considered as 
the preferential administration method for vancomycin to reduce nephrotoxicity risk. Large 
prospective RCTs ultimately need to confirm these results. 
Table 12 Characteristics of studies included in meta-analysis 
Age (years, 
mean) Sex (male, n)
Infusion 
Method 
Vancomycin 
Duration(days, mean) Daily Dose (mean) Nephrotoxicity (n) 
Reference 
CI II CI II CI II CI II CI II CI II 
Wysocki, 1995 (108) 61 67 10 10 13 13 16 16 24 mg/kg/day 12 mg/kg/day 2 3 
Wysocki, 2001 (50) 64 62  45 35 61 58 13 14 NA NA 10 11 
Vuagnat, 2004 (48) NA NA NA NA 23 21 101 66 33.9 mg/kg/day 31.9 mg/kg/day 0 4 
Hutschala, 2009 (105) 59 59 21 72 119 30 9 9 1935 mg/day 1325 mg/day 33 11 
Ingram, 2009 (106) 51 55 25 24 40 40 22 20 NA  NA 4 10 
Schmelzer, 2013 (109) 40 41 32 33 37 36 NA NA NA NA 1 3 
Hanrahan, 2014 
(77)(median) 
59 61 417 260 653 390 5.3 4.4 1.7 g/day 1.5 g/day 161 77 
CI = Continuous infusion, II = Intermittent infusion, NA = Not available 
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Table 13 Comparison of studies including vancomycin administration method, study type, target infection and nephrotoxicity definitions 
Target Concentration Loading Dose Vancomycin Dose Reference CI II CI II CI II Study Type Target Infection Hospital Unit Nephrotoxicity Definition 
Wysocki 1995 (108) 20-
30mg/L 
Peak: 20-
40mg/kg 
Trough 5-
10mg/kg 
15 
mg/kg 
for 1 
hour  
– 30 mg/kg/day 15 mg/kg 
infused over 1 
hour BD11  
Prospective 
Cohort 
• Bacteraemia 
• Pneumonia 
Intensive Care 
Unit 
Rise in serum creatinine of 
44.2 umol/L or more, OR a 
rise of 88.4 uumol /L if the 
initial creatinine was 
265.2umol/L or above. 
Wysocki 2001 (50) 20-25 
mg/L 
10-15 
mg/L 
15 
mg/kg 
for 1 
hour 
_ 30 mg/kg/day 15 mg/kg 
infused over 1 
hour BD 
Randomised 
Control Trial 
• Severe Hospital 
acquired 
infections 
Intensive Care 
Unit 
50 % increase in serum 
creatinine from the day 
treatment was started to the 
end of treatment 
Vuagnat, 2004 (48) Trough 
20-25 
mg/L 
Peak: <50 
mg/L 
Trough: 
20-25 
mg/L 
20 
mg/kg 
over 1 
hour 
_ 40 mg/kg/day 20 mg/kg over 
1 hour BD 
Prospective 
Cohort 
• Osteomyelitis Inpatients until 
vancomycin 
reached steady 
state, then 
managed as 
outpatients  
50 % increase in serum 
creatinine from the day 
treatment was started to the 
end of treatment 
Hutschala, 2009 (105) 20-25 
mg/L 
Trough: 
15 mg/L 
20 
mg/kg 
20 
mg/kg 
0.025mg/kg/min Adjusted 
according to 
trough 
concentration 
Retrospective 
Cohort 
• Infection post 
Cardiac-surgery 
Intensive Care 
Unit 
Increase in SCr of more 
than or equal to 0.3 mg/dL 
or a percentage increase in 
creatinine of at least 50%, 
or a reduction in urine 
output (<0.5ml/kg/hour) for 
more than 6 hours. 
Ingram, 2009  (106) –  – – – Physician guided Physician 
guided 
Retrospective 
Cohort 
• All Outpatient 
parenteral 
antimicrobial 
therapy unit 
50 % increase in serum 
creatinine from the day 
treatment was started to the 
end of treatment 
Schmelzer, 2013 (109) 15-20 
mg/L 
15-20 
mg/L 
20 
mg/kg 
– 0.9 to 2.4 ug/kg/hr 
Altered according 
to renal clearance 
15 mg/kg BD Randomised 
Control Trial 
• Ventilator-
associated 
pneumonia 
Intensive Care 
Unit 
50% increase in serum 
creatinine from baseline 
during treatment. 
Hanrahan, 2014 (77) NA NA NA NA NA NA Retrospective 
Cohort 
• All Intensive Care 
Unit 
An increase in serum 
creatinine concentration 
more than or equal to 50%, 
a decrease in eGFR more 
than or equal to 25%, or a 
serum creatinine 
concentration more than or 
equal to 350 μmol/L (in the 
setting of an acute increase 
≥ 44 μmol/L) 
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BD = Bolus Dosing, sCR = Serum creatinine, NA = Not available, eGFR = estimated Glomerular filtration rate 
 Selection Comparability Exposure/Outcome 
 Representativeness 
of the exposed 
cohort 
Selection of the 
non-exposed 
cohort 
Ascertainment 
of exposure 
Demonstration 
that outcome 
of interest was 
not present at 
start of study 
Comparability 
of cohorts on the 
basis of design 
or analysis 
Assessment of 
outcome 
Was follow-
up long 
enough for 
outcomes to 
occur 
Adequacy of 
follow up of 
cohorts 
Wysocki 1995 (108) * * ND * ** ND * * 
Vuagnat, 2004 (48) SG * * * – B * * * 
Hutschala, 2009 
(105) 
SG * – * ** * * * 
Ingram, 2009 (106) SG * * * – * * * 
Hanrahan, 2014 
(77) 
SG * * * ** * * * 
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Table 14 Newcastle-Ottawa scale study quality analysis for cohort studies  
SG = Selected group of users; ND = No description 
 
 
      52 
 
Table 15 Comparison of continuous infusion and intermittent infusion method in all patients 
included in meta-analysis 
 Risk Ratio Lower Limit Upper Limit Z-Value p-value Relative Weight 
Wysocki 1995 
(108) 
0.667 0.133 3.354 -0.492 0.623 5.88 
Wysocki 2001 (50) 0.864 0.397 1.881 -0.367 0.713 17.19 
Vuagnat, 2004 (48) 0.102 0.006 1.785 -1.563 0.118 2.07 
Hutschala, 2009 
(105) 
0.756 0.435 1.314 -0.991 0.322 24.11 
Ingram, 2009 (106) 0.400 0.137 1.170 -1.673 0.094 11.27 
Schmelzer, 2013 
(109) 
0.324 0.035 2.975 -0.996 0.319 3.35 
Hanrahan, 2014 
(77) 
1.249 0.981 1.589 1.808 0.071 36.13 
Overall 0.799 0.523 1.220 -1.039 0.299  – 
A risk ratio >1 is the increase in risk of the outcome when using intermittent infusion compared 
with continuous infusion. 
 
Table 16 Comparison of continuous infusion and intermittent infusion method in all intensive-
care unit patients included in meta-analysis 
 Risk Ratio Lower Limit Upper Limit Z-Value p-value 
Relative 
Weight 
Wysocki 1995 (108) 0.667 0.133 3.354 -0.492 0.623 2.93 
Wysocki 2001 (50) 0.864 0.397 1.881 -0.367 0.713 11.73 
Hutschala, 2009 
(105) 
0.756 0.435 1.314 -0.991 0.322 21.22 
Schmelzer, 2013 
(109) 
0.324 0.035 2.975 -0.996 0.319 1.70 
Hanrahan, 2014 (77) 1.249 0.981 1.589 1.808 0.071 64.12 
Overall 1.024 0.765 1.371 0.161 0.872 – 
A risk ratio >1 is the increase in risk of the outcome when using intermittent infusion compared with 
continuous infusion 
 Figure 2 Forest plot comparing continuous infusion and intermittent infusion's influence on 
vancomycin-induced nephrotoxicity. 
Continuous infusion, in all but Hanrahan et al (77) was associated with reduced odds of nephrotoxicity. 
Overall RR = 0.799 (0.523-1.220); p = 0.299 
CI = Continuous infusion, II = Intermittent infusion 
 
Figure 3 Forest plot comparing continuous and intermittent infusion's influence on 
vancomycin-induced nephrotoxicity in only those patients who were admitted to an intensive 
care unit. 
Continuous infusion, in all but Hanrahan et al (77), was associated with reduced odds of nephrotoxicity. 
Overall RR = 1.024 (0.765 – 1.371); p = 0.872 
CI = Continuous infusion, II = Intermittent infusion 
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5 Summary of findings, general discussion, future directions and conclusion 
Despite being in use for more than 60 years, the optimal dosing regimen of vancomycin is still 
disputed. With rising resistance to vancomycin it is pertinent that dosing strategies be optimised to 
ensure antibiotic longevity and minimize adverse events. The aim of this thesis was to identify 
independent factors associated with vancomycin-associated nephrotoxicity. 
Two patient populations were studied, and one meta-analysis was performed. The findings are 
summarised below. 
5.1 Summary of results 
Retrospective analyses of two critically ill patient populations were performed. The first analysis 
(77) included 1430 patients who were prescribed vancomycin at any time whilst admitted to the 
University Hospital Intensive Care Unit, Birmingham, UK. The prevalence of vancomycin-
associated nephrotoxicity was 21. Concomitant vasoactive therapy (OR = 1.633), median serum 
vancomycin concentration (OR = 1.112) and duration of therapy (OR= 1.041) were significant 
positive predictors of nephrotoxicity. Furthermore, it was identified that patients who received 
vancomycin by II had significantly greater risk of nephrotoxicity (OR = 8.204) compared with 
those who received vancomycin by CI.  
The second analysis included 159 patients who were prescribed vancomycin whilst admitted to the 
ICU of a tertiary hospital in Brisbane, Queensland, Australia. The prevalence of vancomycin-
associated nephrotoxicity in this cohort was 8.8. Multivariate analysis identified mean trough 
concentration (OR = 1.174), APACHE II score (OR = 1.141), and simultaneous aminoglycoside 
prescription (OR = 18.896) as significant predictors of nephrotoxicity. 
Finally, a meta-analysis and systematic review compare the incidence of vancomycin-associated 
nephrotoxicity between II and CI. A random effects model identified a non-significant trend of 
reduced nephrotoxicity in those who received vancomycin by CI (RR = 0.799).  
5.2 General Discussion 
Previously, robust data identifying predictors of vancomycin-associated nephrotoxicity were 
lacking. Despite studies identifying increased serum trough, daily doses >4 grams per day and 
increased duration of therapy as independent risk factors for toxicity (3,63,64), results were often 
skewed by failure to account for baseline illness severity and small patient cohorts. This thesis 
aimed to provide a large-scale study, to complement literature, and provide categorical conclusions. 
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Here, we have confirmed the results of previous studies with increased serum vancomycin 
concentrations and duration of therapy being identified as independent risk factors for 
nephrotoxicity. Furthermore, concomitant vasoactive therapy, increased illness-severity score 
(APACHE II) and concomitant aminoglycoside use were identified as independent predictors of 
nephrotoxicity. 
The retrospective analysis reported in Chapter 4, to our knowledge, is the largest dataset to suggest 
CI is associated with reduced risk of nephrotoxicity. The meta-analysis confirms these results. 
Interestingly though, the multivariate analysis is at odds with the presented univariate analysis. On 
one hand, multivariate analysis has identified II as being associated with significantly more 
nephrotoxic consequences than CI (OR = 8.204). Conversely, the univariate analysis notes 
increased rates of nephrotoxicity in those treated by CI (24.7% vs. 19.7%). There is however a 
likely explanation for this result. Firstly, hospital policy dictated that administration of vancomycin 
by CI was limited to those with a central line. Immediately, the implication is that those receiving 
vancomycin by CI have greater morbidity, or a central line would not be necessary. Indeed, this is 
reflected by the significantly greater SOFA scores in those receiving vancomycin by CI (7 vs. 5 
respectively; p = <0.001). Furthermore, those in the CI group received greater daily doses (1.7 vs. 
1.5; p = 0.003), were more likely to receive simultaneous vasoactive therapy (71.8% vs. 45.4%; p = 
<0.001), were more likely to die in ICU (26.3% vs. 12.6%; p <0.001) and had a significantly greater 
duration of vancomycin therapy (5.3 vs. 4.4 days; p = <0.001). Ultimately, when controlling for 
these confounders in a logistic regression model, the results above are certainly conceivable. 
Unfortunately, these results did not translate to mortality with II being non-significantly less 
predictive of mortality than CI (OR = 0.735; p = 0.141). This certainly suggests unmeasured 
confounders are present, an unfortunate limitation of retrospective analyses. Alternatively, a 
substantial proportion of patients receiving vancomycin therapy are treated empirically. Thus, it is 
plausible these patients did not have infections responsive to vancomycin. Ultimately, prospective 
randomised controlled trials are necessary to consolidate these results. 
The abovementioned discordance provided an interesting result for the meta-analysis. Given meta-
analyses are formulated using the incidence of events, the abovementioned confounders are not 
accounted for. Ultimately the largest study, and subsequently that with the greatest weighting 
included in analysis (77) was at odds with the remainder. Despite this, though non-significant, using 
a random effects model the final overall RR was 0.799 (p = 0.299).  This, in conjunction with the 
multivariate analysis suggests CI should be the recommended administration method in critically ill 
patients. 
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5.3 Future Directions 
This thesis provides substantial evidence that serum trough concentrations are indeed associated 
with vancomycin-associated nephrotoxicity. Furthermore, we have convincingly shown that CI is 
associated with significantly less nephrotoxicity than II. There are however, a number of limitations 
identified that call for further research, with possible avenues outlined below. 
1. Both original studies included in this thesis study the relationship of vancomycin and 
nephrotoxicity by including the mean (or median) serum concentration in a regression 
model.  Ultimately, by comparing II with CI, we are comparing serum trough 
concentrations with steady-state concentrations, respectively. This is indeed a limitation as 
the AUC is likely to be significantly different, and perhaps, introduce confounders. A 
retrospective study comparing the calculated area under the curve between continuous and 
II would be ideal. 
2. A retrospective analysis cannot demonstrate causality. A well-designed, large 
prospective randomised controlled trial comparing CI and II with respect to both 
incidence of nephrotoxicity and mortality would provide irrefutable conclusions. 
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